MeSH term
Frequency | Condition_Probility | Acute Disease | 3 | 0.0 |
Adult | 663 | 1.0 |
Comparative Study | 180 | 0.0 |
Humans | 2135 | 0.0 |
Patient Selection | 4 | 2.0 |
Albumins/metabolism | 3 | 2.0 |
Albuminuria/*prevention & control | 3 | 3.0 |
Antihypertensive Agents/*therapeutic use | 3 | 1.0 |
Diabetes Mellitus, Type 2/complications/*drug therapy | 3 | 3.0 |
Hypertension/complications/*drug therapy | 3 | 2.0 |
Indoles/*therapeutic use | 3 | 2.0 |
Renin-Angiotensin System/*drug effects | 3 | 2.0 |
Aged | 420 | 1.0 |
Breast Neoplasms/*genetics | 439 | 54.0 |
Carcinoma, Intraductal, Noninfiltrating/*genetics | 3 | 60.0 |
Female | 1618 | 1.0 |
*Genes, BRCA1 | 497 | 97.0 |
*Genes, BRCA2 | 191 | 82.0 |
Middle Aged | 657 | 1.0 |
Mutation | 336 | 3.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 210 | 2.0 |
Research Support, U.S. Gov't, P.H.S. | 620 | 1.0 |
Breast Neoplasms/*diagnosis/genetics | 7 | 38.0 |
Genes, BRCA1 | 168 | 84.0 |
Genes, BRCA2 | 76 | 73.0 |
Magnetic Resonance Imaging | 5 | 0.0 |
Mammography | 12 | 30.0 |
Ultrasonography, Mammary | 3 | 17.0 |
Child | 20 | 0.0 |
Animals | 305 | 0.0 |
BRCA1 Protein/genetics | 58 | 90.0 |
Carrier Proteins/genetics | 2 | 0.0 |
Cell Cycle/genetics | 3 | 2.0 |
Cell Division/genetics | 14 | 3.0 |
English Abstract | 81 | 0.0 |
Mice | 163 | 0.0 |
Mice, Nude | 9 | 0.0 |
Nuclear Proteins/genetics | 4 | 1.0 |
Protein p53/genetics | 10 | 6.0 |
Tumor Suppressor Proteins/genetics | 7 | 10.0 |
*Alternative Splicing | 15 | 2.0 |
Amino Acid Motifs | 20 | 2.0 |
Amino Acid Sequence | 126 | 0.0 |
Antibodies, Monoclonal/metabolism | 4 | 1.0 |
BRCA1 Protein/*chemistry/isolation & purification | 2 | 100.0 |
Breast Neoplasms/genetics | 113 | 52.0 |
*DNA Replication | 4 | 1.0 |
DNA, Neoplasm/*genetics | 14 | 6.0 |
Exons | 78 | 1.0 |
Heterozygote | 142 | 5.0 |
Introns | 26 | 1.0 |
Precipitin Tests | 39 | 1.0 |
Protein Structure, Tertiary | 76 | 1.0 |
*Gene Therapy | 5 | 1.0 |
*Genetic Predisposition to Disease | 106 | 9.0 |
Ovarian Neoplasms/*genetics/prevention & control | 11 | 100.0 |
BRCA1 Protein/*genetics/metabolism | 21 | 100.0 |
BRCA2 Protein/genetics | 29 | 82.0 |
DNA Mutational Analysis/*methods | 18 | 14.0 |
Electrophoresis, Gel, Two-Dimensional | 4 | 1.0 |
Polymorphism, Single-Stranded Conformational | 99 | 4.0 |
Protein Biosynthesis | 6 | 0.0 |
Research Support, Non-U.S. Gov't | 1190 | 0.0 |
Sensitivity and Specificity | 43 | 1.0 |
Transcription, Genetic | 59 | 1.0 |
BRCA1 Protein/*genetics | 206 | 96.0 |
BRCA2 Protein/*genetics | 61 | 82.0 |
DNA Mutational Analysis | 190 | 4.0 |
DNA, Neoplasm/chemistry/genetics | 21 | 17.0 |
Family Health | 94 | 9.0 |
Incidence | 70 | 5.0 |
Ovarian Neoplasms/epidemiology/*genetics/pathology | 2 | 100.0 |
Turkey/epidemiology | 2 | 2.0 |
*Chromosomes, Human | 2 | 3.0 |
*Loss of Heterozygosity | 43 | 11.0 |
*Mutation | 220 | 4.0 |
Ovarian Neoplasms/*genetics/pathology | 16 | 19.0 |
Protein p53/*genetics | 8 | 4.0 |
BRCA1 Protein/metabolism | 28 | 77.0 |
Cell Line | 123 | 0.0 |
DNA Repair | 73 | 11.0 |
DNA-Binding Proteins/metabolism | 17 | 0.0 |
G2 Phase | 15 | 9.0 |
Models, Biological | 28 | 0.0 |
Protein Binding | 79 | 0.0 |
*Protein-Serine-Threonine Kinases | 21 | 2.0 |
S Phase | 16 | 4.0 |
Time Factors | 47 | 0.0 |
cdc25 Phosphatase/metabolism | 3 | 5.0 |
Carrier Proteins/chemistry/*metabolism | 5 | 5.0 |
*Intracellular Signaling Peptides and Proteins | 10 | 1.0 |
Models, Molecular | 25 | 0.0 |
Molecular Sequence Data | 256 | 0.0 |
Mutagenesis, Site-Directed | 21 | 0.0 |
*Phosphoproteins | 7 | 5.0 |
Protein Conformation | 18 | 0.0 |
Protein p53/genetics/*metabolism | 8 | 4.0 |
Breast Neoplasms/epidemiology/*genetics | 96 | 78.0 |
Genetic Counseling/*methods | 6 | 66.0 |
Genetic Screening/methods | 16 | 13.0 |
Ovarian Neoplasms/epidemiology/*genetics | 62 | 88.0 |
Patient Education | 8 | 13.0 |
Prevalence | 48 | 3.0 |
Risk Assessment | 95 | 11.0 |
Risk Factors | 285 | 4.0 |
Adolescent | 50 | 0.0 |
Cluster Analysis | 9 | 4.0 |
Genetic Predisposition to Disease | 212 | 9.0 |
Geography | 3 | 4.0 |
Germ-Line Mutation | 121 | 30.0 |
Registries | 15 | 6.0 |
Sweden/epidemiology | 12 | 11.0 |
Age of Onset | 103 | 8.0 |
Pedigree | 273 | 4.0 |
BRCA1 Protein/genetics/*physiology | 13 | 100.0 |
Cell Differentiation | 5 | 0.0 |
Cell Division | 34 | 0.0 |
Cell Line, Transformed | 16 | 1.0 |
Epithelial Cells/cytology/metabolism | 3 | 5.0 |
Hela Cells | 50 | 0.0 |
Kinetics | 16 | 0.0 |
RNA, Messenger/biosynthesis | 8 | 0.0 |
Tumor Cells, Cultured | 196 | 1.0 |
Codon, Nonsense | 8 | 5.0 |
DNA, Neoplasm/genetics | 60 | 7.0 |
Exons/genetics | 39 | 2.0 |
Frameshift Mutation | 31 | 7.0 |
*Germ-Line Mutation | 135 | 31.0 |
Great Britain/epidemiology | 10 | 9.0 |
Mutation, Missense | 28 | 3.0 |
Neoplastic Syndromes, Hereditary/epidemiology/*genetics | 14 | 70.0 |
Polymerase Chain Reaction | 180 | 1.0 |
Polymorphism, Genetic | 69 | 1.0 |
3T3 Cells | 7 | 0.0 |
BRCA1 Protein/genetics/*metabolism | 38 | 97.0 |
Base Sequence | 207 | 0.0 |
Binding Sites | 58 | 0.0 |
Consensus Sequence | 8 | 1.0 |
DNA/genetics/*metabolism | 2 | 2.0 |
DNA-Binding Proteins/genetics/metabolism | 6 | 1.0 |
Fungal Proteins/genetics | 4 | 2.0 |
Gene Expression Regulation | 20 | 0.0 |
Genes, Reporter | 27 | 1.0 |
*Nuclear Proteins | 20 | 1.0 |
Repressor Proteins/chemistry/genetics/*metabolism | 2 | 4.0 |
*Saccharomyces cerevisiae Proteins | 18 | 1.0 |
Sequence Homology, Amino Acid | 59 | 0.0 |
Trans-Activation (Genetics) | 26 | 1.0 |
Zinc Fingers/genetics/*physiology | 2 | 10.0 |
Aged, 80 and over | 129 | 1.0 |
Breast Neoplasms/*genetics/pathology | 56 | 25.0 |
Gene Amplification | 12 | 1.0 |
In Situ Hybridization, Fluorescence | 32 | 1.0 |
Neoplasm Staging | 41 | 1.0 |
T-Box Domain Proteins/*genetics | 2 | 6.0 |
BRCA1 Protein/*chemistry/*genetics | 4 | 100.0 |
Circular Dichroism | 8 | 1.0 |
Cloning, Molecular | 64 | 0.0 |
In Vitro | 9 | 0.0 |
Protein Denaturation | 3 | 1.0 |
Protein Folding | 7 | 1.0 |
Solutions | 2 | 1.0 |
Spectrometry, Fluorescence | 3 | 0.0 |
Thermodynamics | 6 | 1.0 |
Variation (Genetics) | 20 | 1.0 |
DNA Primers/chemistry | 17 | 1.0 |
Gene Expression Profiling | 8 | 0.0 |
Gene Expression Regulation, Neoplastic | 58 | 2.0 |
Genotype | 91 | 0.0 |
Oligonucleotide Array Sequence Analysis | 15 | 1.0 |
Ovarian Neoplasms/*genetics/metabolism | 7 | 18.0 |
RNA, Messenger/analysis/genetics | 4 | 0.0 |
RNA, Neoplasm/analysis | 6 | 2.0 |
Reverse Transcriptase Polymerase Chain Reaction | 45 | 0.0 |
BRCA2 Protein/*genetics/metabolism | 3 | 60.0 |
Breast Neoplasms/genetics/metabolism | 11 | 24.0 |
Linkage (Genetics) | 60 | 2.0 |
Breast Neoplasms/etiology/*genetics | 16 | 51.0 |
Genes, cdc | 2 | 4.0 |
Immunohistochemistry | 64 | 0.0 |
Point Mutation | 38 | 1.0 |
CpG Islands/genetics | 5 | 3.0 |
*DNA Methylation | 33 | 5.0 |
Embryonic and Fetal Development/genetics | 3 | 3.0 |
Gene Expression Regulation, Developmental | 5 | 0.0 |
Male | 401 | 0.0 |
Oocytes/metabolism | 2 | 1.0 |
BRCA1 Protein/*genetics/*metabolism | 3 | 100.0 |
Cell Survival | 11 | 0.0 |
*Models, Biological | 2 | 1.0 |
Mutation/genetics | 44 | 4.0 |
Organ Specificity | 9 | 0.0 |
Adenocarcinoma/pathology | 3 | 3.0 |
BRCA1 Protein/chemistry/*physiology | 5 | 100.0 |
Breast Neoplasms/pathology | 5 | 4.0 |
COS Cells/metabolism | 2 | 3.0 |
Carcinoma, Ductal, Breast/pathology | 2 | 16.0 |
Cell Cycle | 38 | 3.0 |
Cercopithecus aethiops | 3 | 0.0 |
Neoplasm Proteins/metabolism | 5 | 1.0 |
Promoter Regions (Genetics) | 47 | 1.0 |
Sequence Deletion | 52 | 2.0 |
*Trans-Activation (Genetics) | 16 | 2.0 |
Transfection | 90 | 0.0 |
Tumor Cells, Cultured/metabolism | 2 | 1.0 |
Adenoviridae/genetics | 9 | 1.0 |
*Apoptosis | 8 | 0.0 |
BRCA1 Protein/*metabolism | 69 | 94.0 |
Caspases/metabolism | 2 | 0.0 |
Enzyme Activation | 14 | 0.0 |
Enzyme Inhibitors/pharmacology | 13 | 0.0 |
Genes, Dominant | 16 | 1.0 |
Immunoblotting | 11 | 0.0 |
In Situ Nick-End Labeling | 3 | 0.0 |
*JNK Mitogen-Activated Protein Kinases | 2 | 2.0 |
Mitogen-Activated Protein Kinase 3 | 3 | 0.0 |
Mitosis | 24 | 5.0 |
Phosphorylation | 68 | 0.0 |
Signal Transduction | 31 | 0.0 |
BRCA1 Protein/*chemistry | 5 | 100.0 |
Genetic Vectors | 20 | 1.0 |
Glutathione Transferase/metabolism | 11 | 1.0 |
Two-Hybrid System Techniques | 19 | 1.0 |
Asia/ethnology | 2 | 6.0 |
Saudi Arabia/epidemiology | 2 | 11.0 |
Alleles | 83 | 1.0 |
DNA Damage | 75 | 9.0 |
Fanconi Anemia/*genetics | 4 | 8.0 |
Fibroblasts | 4 | 0.0 |
Gene Silencing | 10 | 3.0 |
Genetic Complementation Test | 10 | 1.0 |
Homozygote | 12 | 0.0 |
Mitomycin/pharmacology | 6 | 6.0 |
Phenotype | 86 | 0.0 |
RNA, Messenger/genetics/metabolism | 21 | 0.0 |
BRCA1 Protein/analysis | 5 | 100.0 |
BRCA2 Protein/analysis | 2 | 100.0 |
Breast/*metabolism | 3 | 5.0 |
Breast Neoplasms/*genetics/metabolism | 25 | 23.0 |
Cell Division/drug effects | 15 | 0.0 |
Chromatography, Affinity | 3 | 0.0 |
Eicosapentaenoic Acid/pharmacology | 2 | 22.0 |
Fatty Acids, Unsaturated/*pharmacology | 2 | 6.0 |
Gene Expression/drug effects | 5 | 0.0 |
Genes, BRCA1/*drug effects | 4 | 80.0 |
Inhibitory Concentration 50 | 3 | 1.0 |
Polymerase Chain Reaction/methods | 25 | 2.0 |
RNA, Messenger/analysis | 12 | 0.0 |
*Genes, p53 | 23 | 4.0 |
Ovarian Neoplasms/diagnosis/*genetics | 10 | 83.0 |
Breast Neoplasms/ethnology/*genetics | 16 | 80.0 |
Ovarian Neoplasms/ethnology/*genetics | 8 | 88.0 |
Portugal/epidemiology | 2 | 11.0 |
Prospective Studies | 20 | 0.0 |
Spain/epidemiology | 10 | 6.0 |
Apoptosis/genetics/*physiology | 2 | 5.0 |
DNA/*metabolism | 3 | 0.0 |
*DNA Repair | 42 | 6.0 |
Neoplasms/*genetics | 20 | 7.0 |
Protein p53/genetics/metabolism | 7 | 7.0 |
Crystallography, X-Ray | 9 | 1.0 |
*DNA Damage | 49 | 8.0 |
Nuclear Proteins | 3 | 7.0 |
Peptide Library | 3 | 2.0 |
Peptide Mapping | 2 | 0.0 |
Structure-Activity Relationship | 15 | 0.0 |
Trans-Activators/metabolism | 3 | 0.0 |
Transcription Factors | 4 | 4.0 |
Breast Neoplasms/diagnosis/*genetics | 22 | 78.0 |
*Computer Simulation | 3 | 4.0 |
Genetic Screening/economics/*methods | 3 | 37.0 |
Mutation/*genetics | 66 | 5.0 |
Ovarian Neoplasms/diagnosis/genetics | 9 | 100.0 |
Predictive Value of Tests | 38 | 1.0 |
Probability | 23 | 3.0 |
Analysis of Variance | 6 | 0.0 |
Follow-Up Studies | 25 | 0.0 |
*Mastectomy, Segmental | 4 | 57.0 |
Neoplasm Recurrence, Local | 8 | 1.0 |
Ovarian Neoplasms/genetics | 111 | 73.0 |
Survival Rate | 25 | 1.0 |
Treatment Outcome | 15 | 0.0 |
Breast Neoplasms/epidemiology/*genetics/prevention & control | 10 | 100.0 |
*Decision Making, Computer-Assisted | 2 | 50.0 |
Genetic Predisposition to Disease/epidemiology | 3 | 3.0 |
Genetic Screening/*methods | 20 | 14.0 |
Heterozygote Detection | 32 | 5.0 |
Ovarian Neoplasms/epidemiology/*genetics/prevention & control | 9 | 100.0 |
Reproducibility of Results | 21 | 1.0 |
Retrospective Studies | 42 | 1.0 |
United States/epidemiology | 20 | 5.0 |
Breast Neoplasms/genetics/*radiography | 2 | 100.0 |
Mammography/*methods | 2 | 50.0 |
Blotting, Western | 39 | 0.0 |
Cell Line, Tumor | 37 | 1.0 |
Radiation Tolerance/*genetics | 5 | 8.0 |
Amino Acid Substitution/genetics | 6 | 2.0 |
BRCA1 Protein/*chemistry/genetics | 5 | 100.0 |
Ligands | 7 | 0.0 |
*Mutagenesis, Site-Directed | 2 | 2.0 |
Protein Structure, Tertiary/genetics | 6 | 2.0 |
*Sequence Deletion | 23 | 5.0 |
Case-Control Studies | 85 | 1.0 |
Mass Screening | 16 | 8.0 |
Cells, Cultured | 33 | 0.0 |
Codon | 10 | 2.0 |
Conserved Sequence | 20 | 1.0 |
Epithelial Cells/metabolism/pathology | 5 | 10.0 |
Epitopes | 5 | 0.0 |
Gene Deletion | 28 | 1.0 |
Open Reading Frames | 3 | 0.0 |
Breast Neoplasms/*genetics/*pathology | 16 | 24.0 |
CpG Islands | 11 | 3.0 |
DNA/metabolism | 15 | 1.0 |
Lymphatic Metastasis | 17 | 1.0 |
Multivariate Analysis | 18 | 1.0 |
Odds Ratio | 31 | 2.0 |
Phylogeny | 6 | 0.0 |
Sulfites/pharmacology | 2 | 6.0 |
Chromatography, High Pressure Liquid | 5 | 0.0 |
*Chromosomes, Human, Pair 17 | 67 | 13.0 |
Cohort Studies | 43 | 1.0 |
*Genome | 2 | 1.0 |
*Linkage (Genetics) | 13 | 1.0 |
Models, Genetic | 45 | 2.0 |
Sequence Analysis, DNA | 40 | 1.0 |
DNA Primers | 79 | 1.0 |
*Exons | 7 | 1.0 |
RNA, Messenger/*genetics | 3 | 0.0 |
Alternative Splicing/*genetics | 5 | 3.0 |
Exons/*genetics | 9 | 2.0 |
Point Mutation/*genetics | 2 | 0.0 |
Cell Transformation, Neoplastic/*genetics | 5 | 2.0 |
DNA, Complementary/genetics | 13 | 0.0 |
Epithelial Cells/cytology/physiology | 2 | 6.0 |
*Gene Expression Regulation, Neoplastic | 27 | 1.0 |
Kidney | 4 | 1.0 |
BRCA1 Protein/drug effects/genetics/*metabolism | 2 | 100.0 |
*Cell Cycle Proteins | 19 | 1.0 |
DNA Repair/*physiology | 7 | 6.0 |
Doxorubicin/pharmacology | 9 | 4.0 |
Proteins/genetics | 18 | 2.0 |
*Proto-Oncogene Proteins | 5 | 0.0 |
Radiation, Ionizing | 22 | 15.0 |
Breast Neoplasms/epidemiology/genetics/*prevention & control | 6 | 100.0 |
Ovarian Neoplasms/epidemiology/genetics/*prevention & control | 5 | 100.0 |
*Ovariectomy | 17 | 39.0 |
Peritoneal Neoplasms/epidemiology/genetics/*prevention & control | 2 | 100.0 |
Proportional Hazards Models | 14 | 2.0 |
Risk | 64 | 7.0 |
Actuarial Analysis | 3 | 4.0 |
Disease-Free Survival | 14 | 1.0 |
Fallopian Tubes/*surgery | 3 | 75.0 |
Amino Acid Substitution | 13 | 0.0 |
DNA Repair/*genetics | 21 | 6.0 |
DNA-Binding Proteins/*genetics | 21 | 1.0 |
Chromosome Mapping | 94 | 1.0 |
Chromosomes, Human, Pair 4 | 2 | 1.0 |
Gene Targeting | 4 | 1.0 |
Genetic Markers | 113 | 3.0 |
Nucleic Acid Hybridization | 20 | 1.0 |
Jews | 10 | 14.0 |
Comet Assay | 3 | 4.0 |
Radiation Tolerance/genetics | 6 | 12.0 |
*DNA Mutational Analysis | 12 | 7.0 |
DNA, Neoplasm/analysis | 39 | 4.0 |
Neoplastic Syndromes, Hereditary/*genetics | 13 | 30.0 |
Ovarian Neoplasms/*genetics | 236 | 67.0 |
Spain | 11 | 3.0 |
Genes, BRCA1/physiology | 10 | 90.0 |
Genes, BRCA2/physiology | 7 | 77.0 |
Genetic Screening | 132 | 15.0 |
Phosphoric Monoester Hydrolases/genetics | 5 | 6.0 |
Genes, BRCA1/*physiology | 33 | 100.0 |
Up-Regulation | 14 | 0.0 |
Breast Neoplasms | 10 | 3.0 |
Dose-Response Relationship, Drug | 18 | 0.0 |
*Down-Regulation | 4 | 1.0 |
RNA, Messenger | 4 | 0.0 |
DNA Fingerprinting/*methods | 3 | 5.0 |
Genetic Predisposition to Disease/genetics | 30 | 7.0 |
DNA Methylation | 24 | 3.0 |
Survival Analysis | 36 | 1.0 |
Breast Neoplasms/genetics/*pathology/therapy | 3 | 100.0 |
Combined Modality Therapy | 4 | 0.0 |
Mastectomy, Segmental | 2 | 11.0 |
Chi-Square Distribution | 9 | 1.0 |
Immunoenzyme Techniques | 9 | 0.0 |
Immunophenotyping | 4 | 0.0 |
Logistic Models | 20 | 2.0 |
Receptors, Estrogen/genetics | 2 | 3.0 |
Electrophoresis | 4 | 1.0 |
Antineoplastic Agents, Hormonal/*therapeutic use | 7 | 9.0 |
Breast Neoplasms/diagnosis/*genetics/*prevention & control | 5 | 100.0 |
*Genetic Screening | 58 | 29.0 |
Mastectomy | 19 | 28.0 |
Ovariectomy | 29 | 23.0 |
Questionnaires | 22 | 4.0 |
Tamoxifen/*therapeutic use | 10 | 12.0 |
Age Factors | 62 | 2.0 |
Bias (Epidemiology) | 5 | 9.0 |
Breast Neoplasms/*epidemiology/*genetics | 20 | 55.0 |
*Gene Frequency | 2 | 0.0 |
CHO Cells | 7 | 0.0 |
*Gene Expression Profiling | 3 | 0.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 6 | 2.0 |
Hamsters | 13 | 0.0 |
Attitude to Health | 11 | 25.0 |
Primary Prevention/*methods | 4 | 44.0 |
Breast Neoplasms/diagnosis/ethnology/*genetics | 2 | 100.0 |
Canada | 8 | 5.0 |
Family | 41 | 11.0 |
France | 11 | 3.0 |
Gene Frequency | 67 | 1.0 |
Ovarian Neoplasms/diagnosis/ethnology/*genetics | 2 | 100.0 |
Antineoplastic Agents/therapeutic use | 3 | 1.0 |
Clinical Trials | 9 | 0.0 |
*Heterozygote | 38 | 11.0 |
Cost-Benefit Analysis | 6 | 5.0 |
Databases, Factual | 7 | 2.0 |
Genetic Counseling/*economics | 2 | 100.0 |
Age Distribution | 20 | 6.0 |
Genetic Predisposition to Disease/*epidemiology | 5 | 20.0 |
Antineoplastic Agents, Hormonal/therapeutic use | 8 | 17.0 |
Breast Neoplasms/*genetics/metabolism/prevention & control | 2 | 100.0 |
Contraceptives, Oral, Hormonal/adverse effects | 3 | 23.0 |
Estrogens/metabolism | 6 | 7.0 |
Genetic Predisposition to Disease/*genetics | 29 | 7.0 |
Tamoxifen/therapeutic use | 16 | 25.0 |
BRCA1 Protein/*analysis | 6 | 100.0 |
Breast Neoplasms/chemistry | 2 | 11.0 |
Ovarian Neoplasms/chemistry | 2 | 22.0 |
*Promoter Regions (Genetics) | 18 | 0.0 |
Protein Processing, Post-Translational | 3 | 0.0 |
RNA, Messenger/metabolism | 22 | 0.0 |
Ataxia Telangiectasia/genetics | 15 | 31.0 |
Breast Neoplasms, Male/etiology/*genetics | 3 | 100.0 |
Genes, p53/*genetics | 14 | 4.0 |
Hamartoma Syndrome, Multiple/genetics | 6 | 37.0 |
Li-Fraumeni Syndrome/genetics | 11 | 68.0 |
Peutz-Jeghers Syndrome/genetics | 3 | 42.0 |
Carrier Proteins/chemistry/genetics/*physiology | 2 | 5.0 |
Evolution, Molecular | 11 | 1.0 |
Genes, Tumor Suppressor | 57 | 6.0 |
Sequence Alignment | 24 | 0.0 |
*Tumor Suppressor Proteins | 60 | 4.0 |
*Ubiquitin-Protein Ligases | 41 | 7.0 |
*DNA-Binding Proteins | 32 | 1.0 |
Nuclear Proteins/metabolism | 16 | 1.0 |
Proteins/metabolism | 3 | 0.0 |
Australia | 11 | 5.0 |
Blotting, Southern | 19 | 0.0 |
Germ-Line Mutation/*genetics | 56 | 35.0 |
Great Britain | 7 | 2.0 |
Introns/genetics | 8 | 1.0 |
Promoter Regions (Genetics)/*genetics | 11 | 1.0 |
Recombination, Genetic/*genetics | 6 | 8.0 |
Restriction Mapping | 7 | 0.0 |
Sequence Deletion/*genetics | 9 | 8.0 |
Carrier Proteins/*chemistry/*metabolism | 4 | 9.0 |
Dimerization | 23 | 1.0 |
Histones/metabolism | 9 | 3.0 |
Lysine/chemistry | 2 | 2.0 |
Recombinant Proteins/metabolism | 10 | 0.0 |
Ubiquitin/*metabolism | 10 | 5.0 |
*Amino Acid Substitution | 2 | 2.0 |
Australia/epidemiology | 6 | 9.0 |
*Polymorphism, Genetic | 22 | 0.0 |
Regression Analysis | 7 | 0.0 |
*Mutation, Missense | 14 | 2.0 |
Ovarian Neoplasms/etiology/*genetics | 6 | 66.0 |
Active Transport, Cell Nucleus | 3 | 1.0 |
Cell Nucleus/metabolism | 32 | 1.0 |
Microscopy, Confocal | 4 | 0.0 |
Microscopy, Fluorescence | 20 | 1.0 |
Plasmids/metabolism | 15 | 1.0 |
Neoplasm Proteins/*genetics | 315 | 29.0 |
Reproductive History | 5 | 31.0 |
Gene Expression/*genetics | 2 | 1.0 |
Heterozygote Detection/methods | 5 | 20.0 |
Breast Neoplasms/genetics/*pathology | 16 | 37.0 |
Chromosomes, Human, Pair 17/*genetics | 20 | 11.0 |
Lod Score | 29 | 2.0 |
Microsatellite Repeats | 35 | 2.0 |
RNA Helicases/*genetics | 2 | 14.0 |
Philippines | 2 | 6.0 |
Evolution | 4 | 1.0 |
*Evolution, Molecular | 4 | 0.0 |
*Selection (Genetics) | 3 | 4.0 |
BRCA1 Protein/genetics/metabolism | 11 | 84.0 |
DNA Helicases/genetics/*metabolism | 2 | 9.0 |
Gamma Rays | 20 | 8.0 |
Hydroxyurea/pharmacology | 5 | 9.0 |
Nuclear Proteins/genetics/*metabolism | 10 | 2.0 |
Nucleic Acid Synthesis Inhibitors/pharmacology | 2 | 1.0 |
Protein-Serine-Threonine Kinases/genetics/metabolism | 5 | 4.0 |
Breast Neoplasms/*enzymology | 2 | 3.0 |
Carrier Proteins/*metabolism | 9 | 1.0 |
Down-Regulation | 21 | 1.0 |
Electrophoresis, Polyacrylamide Gel | 14 | 0.0 |
*Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Proto-Oncogene Proteins c-myc/*metabolism | 2 | 2.0 |
Anticarcinogenic Agents/therapeutic use | 9 | 60.0 |
Breast Neoplasms/drug therapy/genetics/*prevention & control | 2 | 100.0 |
Menopause | 5 | 2.0 |
Receptors, Estrogen/metabolism | 13 | 4.0 |
Selective Estrogen Receptor Modulators/therapeutic use | 4 | 44.0 |
Breast Neoplasms/*prevention & control | 3 | 33.0 |
Raloxifene/therapeutic use | 4 | 80.0 |
Escherichia coli/genetics | 4 | 0.0 |
*Frameshift Mutation | 12 | 6.0 |
Plasmids | 4 | 0.0 |
Aphidicolin/pharmacology | 4 | 8.0 |
Apoptosis | 23 | 1.0 |
DNA Ligases/*metabolism | 2 | 10.0 |
DNA-Directed DNA Polymerase/antagonists & inhibitors | 2 | 28.0 |
Drug Interactions | 2 | 0.0 |
Electrophoresis, Gel, Pulsed-Field | 3 | 1.0 |
Enzyme Inhibitors/*pharmacology | 3 | 0.0 |
Genetic Diseases, Inborn/genetics | 4 | 9.0 |
Recombination, Genetic | 26 | 2.0 |
Adenomatous Polyposis Coli/genetics | 5 | 16.0 |
Lung Neoplasms/genetics | 2 | 3.0 |
Molecular Biology | 5 | 2.0 |
Stomach Neoplasms/genetics | 2 | 8.0 |
DNA Mutational Analysis/methods | 13 | 6.0 |
Genetic Counseling | 49 | 28.0 |
Genetic Predisposition to Disease/epidemiology/genetics | 2 | 9.0 |
Medical History Taking | 8 | 21.0 |
Ontario/epidemiology | 5 | 20.0 |
*Chromosome Aberrations | 8 | 1.0 |
Chromosomes, Human, Pair 11/genetics | 2 | 0.0 |
Chromosomes, Human, Pair 17/genetics | 20 | 11.0 |
Receptor, erbB-2/analysis | 6 | 6.0 |
Adenocarcinoma/*genetics | 8 | 5.0 |
Biosensing Techniques | 2 | 3.0 |
Colorectal Neoplasms/*genetics | 6 | 2.0 |
Genes, Tumor Suppressor/*physiology | 5 | 4.0 |
Genes, ras/*genetics | 2 | 2.0 |
Polymerase Chain Reaction/*methods | 11 | 2.0 |
Founder Effect | 35 | 27.0 |
Jews/*genetics | 64 | 43.0 |
Ovarian Neoplasms/*epidemiology/*genetics | 6 | 100.0 |
Breast Neoplasms, Male/genetics | 31 | 79.0 |
Jews/genetics | 39 | 43.0 |
Antineoplastic Agents/pharmacology | 5 | 0.0 |
DNA, Neoplasm/metabolism | 2 | 1.0 |
Mice, Inbred C57BL | 10 | 0.0 |
Mice, Transgenic | 12 | 0.0 |
RNA, Neoplasm/metabolism | 3 | 3.0 |
Breast Neoplasms/*genetics/prevention & control | 18 | 100.0 |
Premenopause | 4 | 4.0 |
Prognosis | 75 | 1.0 |
Loss of Heterozygosity/*genetics | 6 | 6.0 |
Alternative Splicing | 10 | 0.0 |
DNA Damage/radiation effects | 3 | 13.0 |
DNA Repair/radiation effects | 3 | 23.0 |
Micronucleus Tests | 4 | 8.0 |
Mutagens/*toxicity | 3 | 2.0 |
Reference Values | 14 | 0.0 |
BRCA1 Protein/*biosynthesis/genetics | 6 | 75.0 |
Breast Neoplasms/genetics/*metabolism/pathology | 8 | 18.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Chromosomes, Human, Pair 17 | 39 | 12.0 |
Gene Dosage | 6 | 1.0 |
*Genes, erbB-2 | 2 | 2.0 |
Loss of Heterozygosity | 48 | 5.0 |
Carcinoma/*genetics | 13 | 12.0 |
Proteins/*genetics | 10 | 0.0 |
Bromodeoxyuridine/pharmacology | 3 | 5.0 |
CDC2 Protein Kinase/metabolism | 2 | 1.0 |
Cell Cycle Proteins/*physiology | 4 | 7.0 |
DNA-Binding Proteins/*physiology | 3 | 0.0 |
Fibroblasts/metabolism | 6 | 0.0 |
Flow Cytometry | 22 | 0.0 |
Nuclear Proteins/*physiology | 7 | 5.0 |
Transgenes | 2 | 0.0 |
Breast Neoplasms/diagnosis/*genetics/therapy | 3 | 37.0 |
Germ-Line Mutation/genetics | 15 | 21.0 |
Japan | 16 | 1.0 |
Ovarian Neoplasms/diagnosis/*genetics/therapy | 2 | 66.0 |
Disease Progression | 15 | 0.0 |
Plasmids/genetics | 5 | 1.0 |
Transplantation, Heterologous | 3 | 0.0 |
Ovarian Neoplasms/blood/*genetics | 3 | 60.0 |
Tumor Suppressor Proteins/*genetics | 3 | 2.0 |
X Chromosome/genetics | 2 | 1.0 |
Chromosome Deletion | 11 | 1.0 |
Regulatory Sequences, Nucleic Acid/genetics | 2 | 2.0 |
England/epidemiology | 2 | 3.0 |
3' Untranslated Regions | 2 | 1.0 |
5' Untranslated Regions | 2 | 1.0 |
Electrophoresis, Capillary | 4 | 8.0 |
Nucleic Acid Conformation | 5 | 0.0 |
Ovarian Neoplasms/metabolism | 3 | 8.0 |
*Protein Biosynthesis | 5 | 1.0 |
Carrier Proteins/*chemistry | 4 | 6.0 |
Protein p53/*chemistry | 2 | 25.0 |
Rats | 27 | 0.0 |
Cell Cycle Proteins/*metabolism | 12 | 3.0 |
DNA Damage/*physiology | 5 | 11.0 |
*Drosophila Proteins | 7 | 0.0 |
Nuclear Proteins/*metabolism | 15 | 2.0 |
Protein-Serine-Threonine Kinases/*metabolism | 10 | 1.0 |
S Phase/*physiology | 2 | 4.0 |
Chromosomal Proteins, Non-Histone/metabolism | 2 | 7.0 |
Ovarian Neoplasms/*diagnosis/genetics | 2 | 100.0 |
Breast Neoplasms/*genetics/*prevention & control | 12 | 92.0 |
*Models, Theoretical | 2 | 3.0 |
Receptors, Estrogen/*analysis | 3 | 1.0 |
Carcinoma/*genetics/pathology | 4 | 6.0 |
*Cell Division | 2 | 1.0 |
Asian Continental Ancestry Group/*genetics | 4 | 1.0 |
China/ethnology | 4 | 2.0 |
*Founder Effect | 41 | 33.0 |
Genetics, Population | 7 | 1.0 |
Breast Neoplasms/diagnosis/genetics | 8 | 72.0 |
Gene Frequency/*genetics | 8 | 5.0 |
*Alleles | 14 | 1.0 |
Cell Extracts/pharmacology | 2 | 10.0 |
DNA Repair/drug effects/*genetics | 2 | 22.0 |
*Models, Genetic | 12 | 9.0 |
Blotting, Northern | 22 | 0.0 |
COS Cells | 18 | 0.0 |
Carrier Proteins/genetics/*metabolism | 9 | 2.0 |
DNA-Binding Proteins/genetics/*metabolism | 7 | 0.0 |
*Gene Expression Regulation, Developmental | 4 | 0.0 |
*Genes, Tumor Suppressor | 67 | 6.0 |
In Situ Hybridization | 7 | 0.0 |
Proteins/genetics/*metabolism | 3 | 0.0 |
Subcellular Fractions/metabolism | 7 | 2.0 |
Breast Neoplasms/*etiology/*genetics | 2 | 22.0 |
*DNA, Neoplasm | 2 | 20.0 |
Genetic Heterogeneity | 6 | 2.0 |
Tumor Markers, Biological/*genetics | 10 | 9.0 |
Breast Neoplasms/diagnosis/*ethnology/*genetics | 2 | 100.0 |
Breast Neoplasms/genetics/pathology | 10 | 29.0 |
Fluorescent Antibody Technique | 17 | 0.0 |
Protein Kinases/*metabolism | 4 | 1.0 |
BRCA1 Protein/deficiency/*metabolism | 2 | 100.0 |
Carcinoma, Hepatocellular | 2 | 0.0 |
Cell Nucleus/*metabolism | 9 | 2.0 |
DNA Repair/physiology | 5 | 14.0 |
DNA-Binding Proteins/*metabolism | 18 | 0.0 |
Liver Neoplasms | 2 | 0.0 |
*Ultraviolet Rays | 4 | 1.0 |
BRCA2 Protein/*metabolism | 5 | 50.0 |
Cell Cycle/physiology | 8 | 2.0 |
Cell Transformation, Neoplastic | 7 | 1.0 |
Breast Neoplasms/*ethnology/*genetics | 8 | 72.0 |
Ethnic Groups | 4 | 1.0 |
Centrosome/*metabolism | 2 | 10.0 |
Lysine/genetics/metabolism | 2 | 10.0 |
RNA, Small Interfering/metabolism | 7 | 3.0 |
Tumor Suppressor Proteins/metabolism | 2 | 1.0 |
Biopsy | 3 | 0.0 |
Breast Neoplasms/*diagnosis/*genetics | 6 | 66.0 |
False Positive Reactions | 2 | 0.0 |
Physical Examination | 5 | 18.0 |
Azacitidine/*analogs & derivatives/pharmacology | 3 | 4.0 |
Brain Neoplasms/*genetics | 2 | 1.0 |
CpG Islands/*genetics | 3 | 3.0 |
*DNA Methylation/drug effects | 2 | 10.0 |
Epigenesis, Genetic | 4 | 15.0 |
Neoplasm Proteins/*metabolism | 7 | 1.0 |
Sex Factors | 4 | 0.0 |
Protein-Serine-Threonine Kinases/*genetics/metabolism | 3 | 5.0 |
Ataxia Telangiectasia/*genetics | 5 | 7.0 |
DNA Replication/physiology | 2 | 6.0 |
Dose-Response Relationship, Radiation | 11 | 3.0 |
Nuclear Proteins/genetics/metabolism | 4 | 2.0 |
Protein-Serine-Threonine Kinases/genetics/*physiology | 2 | 5.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Pregnancy | 24 | 0.0 |
Signal Transduction/physiology | 4 | 0.0 |
Carrier Proteins/*genetics | 7 | 0.0 |
Breast Neoplasms/genetics/prevention & control | 3 | 75.0 |
*Communication | 3 | 27.0 |
Motivation | 4 | 21.0 |
*Nuclear Family | 2 | 11.0 |
Ovarian Neoplasms/genetics/prevention & control | 4 | 100.0 |
Chromosome Breakage | 5 | 6.0 |
Colony-Forming Units Assay | 3 | 0.0 |
*Haplotypes | 4 | 1.0 |
Base Pairing | 2 | 3.0 |
Breast Neoplasms/epidemiology/genetics | 17 | 80.0 |
DNA/genetics | 7 | 0.0 |
Feasibility Studies | 6 | 2.0 |
Haplotypes/genetics | 9 | 1.0 |
Nucleic Acid Denaturation | 2 | 2.0 |
Smoking | 6 | 1.0 |
Germany/epidemiology | 4 | 3.0 |
Neoplasms, Multiple Primary/epidemiology/genetics | 4 | 80.0 |
Ovarian Neoplasms/epidemiology/genetics | 21 | 100.0 |
RNA Splicing/genetics | 3 | 2.0 |
Breast Neoplasms, Male/epidemiology/*genetics | 2 | 40.0 |
*Genetic Screening/economics | 2 | 50.0 |
CA-125 Antigen/blood | 4 | 13.0 |
Ovarian Neoplasms/*epidemiology/*genetics/prevention & control | 2 | 100.0 |
Tumor Markers, Biological/blood | 3 | 1.0 |
Breast Neoplasms/epidemiology/ethnology/*genetics | 3 | 100.0 |
Codon, Nonsense/genetics | 5 | 8.0 |
European Continental Ancestry Group/genetics | 9 | 1.0 |
Frameshift Mutation/genetics | 8 | 10.0 |
Heteroduplex Analysis | 7 | 9.0 |
Automation | 2 | 3.0 |
Conserved Sequence/genetics | 4 | 2.0 |
Hydrogen Bonding | 3 | 1.0 |
Zinc/metabolism | 2 | 2.0 |
Chromosomes, Human, Pair 13/*genetics | 9 | 12.0 |
Europe | 6 | 2.0 |
North America | 4 | 7.0 |
BRCA1 Protein/*chemistry/*metabolism | 4 | 100.0 |
Ligases/*metabolism | 3 | 3.0 |
Ubiquitin/metabolism | 4 | 1.0 |
Ubiquitin-Protein Ligases | 3 | 1.0 |
Breast Neoplasms/genetics/psychology | 3 | 100.0 |
*Genetic Counseling | 25 | 52.0 |
Genetic Screening/*psychology | 24 | 80.0 |
*Stress, Psychological | 3 | 20.0 |
Estrogen Receptor alpha | 10 | 4.0 |
Prostatic Neoplasms/genetics/metabolism | 2 | 15.0 |
RNA, Messenger/biosynthesis/genetics | 5 | 0.0 |
Receptors, Estrogen/*antagonists & inhibitors/physiology | 2 | 66.0 |
Trans-Activation (Genetics)/physiology | 2 | 2.0 |
Conserved Sequence/*genetics | 2 | 3.0 |
Haplotypes/*genetics | 5 | 2.0 |
Mutagenesis, Insertional/genetics | 2 | 8.0 |
Sweden | 4 | 1.0 |
BRCA1 Protein/*analysis/immunology | 2 | 100.0 |
Nutrition | 3 | 7.0 |
DNA Damage/drug effects/genetics/radiation effects | 2 | 50.0 |
Mutagens/pharmacology | 3 | 7.0 |
Ultraviolet Rays | 28 | 4.0 |
Proteins/*metabolism | 7 | 0.0 |
Transcription Factors/*chemistry/metabolism | 3 | 6.0 |
Carrier Proteins/*chemistry/metabolism | 3 | 7.0 |
Electrostatics | 2 | 1.0 |
Cystadenocarcinoma, Papillary/*genetics | 3 | 100.0 |
Uterine Neoplasms/*genetics | 3 | 7.0 |
CA-125 Antigen/analysis | 3 | 15.0 |
Contraceptives, Oral/therapeutic use | 3 | 50.0 |
Ovariectomy/methods | 2 | 66.0 |
Radioimmunoassay | 2 | 0.0 |
United States | 22 | 2.0 |
Gene Expression | 34 | 0.0 |
Genes, BRCA2/*physiology | 6 | 54.0 |
Transcription, Genetic/physiology | 3 | 1.0 |
BRCA2 Protein/metabolism | 2 | 40.0 |
Breast Neoplasms/*genetics/metabolism/pathology | 8 | 15.0 |
Oligonucleotide Array Sequence Analysis/methods | 2 | 2.0 |
Cell Cycle Proteins/metabolism | 11 | 3.0 |
DNA Replication | 9 | 2.0 |
K562 Cells | 4 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 10 | 1.0 |
Greece | 2 | 2.0 |
BRCA1 Protein/chemistry/*metabolism | 7 | 100.0 |
Breast Neoplasms/metabolism | 7 | 5.0 |
DNA, Complementary/metabolism | 11 | 0.0 |
Epithelial Cells/metabolism | 4 | 1.0 |
Nuclear Proteins/chemistry/*metabolism | 3 | 5.0 |
Recombinant Fusion Proteins/metabolism | 8 | 0.0 |
Transcription Factors/chemistry/*metabolism | 2 | 1.0 |
*Oncogenes | 25 | 6.0 |
Bleomycin/pharmacology | 2 | 7.0 |
Fanconi Anemia/genetics | 3 | 25.0 |
Hybrid Cells | 6 | 0.0 |
Mechlorethamine/pharmacology | 2 | 66.0 |
Mutagens/*pharmacology | 4 | 13.0 |
Czech Republic | 2 | 4.0 |
DNA/chemistry/genetics | 4 | 0.0 |
Chromatin/*genetics | 2 | 14.0 |
DNA Mutational Analysis/economics/methods | 3 | 100.0 |
Research Design | 10 | 11.0 |
Single-Blind Method | 2 | 0.0 |
Temperature | 8 | 0.0 |
Gene Library | 13 | 0.0 |
Peptide Fragments/genetics | 2 | 2.0 |
Breast Neoplasms/genetics/*metabolism | 10 | 17.0 |
Mammals | 4 | 1.0 |
Mutation/physiology | 2 | 1.0 |
Nuclear Proteins/*genetics/metabolism | 3 | 2.0 |
Yeasts | 3 | 4.0 |
Catalysis | 6 | 0.0 |
RNA Interference | 5 | 1.0 |
Recombinant Fusion Proteins/chemistry/metabolism | 3 | 1.0 |
Saccharomyces cerevisiae/genetics | 4 | 0.0 |
Trans-Activators/*metabolism | 4 | 0.0 |
*Transcription, Genetic | 15 | 0.0 |
*Chromosome Deletion | 17 | 2.0 |
*Point Mutation | 13 | 1.0 |
Luciferases/genetics | 2 | 0.0 |
Mutation, Missense/*genetics | 7 | 3.0 |
Transcription, Genetic/*genetics | 5 | 2.0 |
Variation (Genetics)/genetics | 3 | 1.0 |
BRCA2 Protein/genetics/metabolism | 2 | 40.0 |
DNA Damage/genetics | 8 | 19.0 |
Macromolecular Substances | 11 | 0.0 |
Syndrome | 20 | 1.0 |
*Aneuploidy | 4 | 4.0 |
Calcium-Binding Proteins/*genetics | 2 | 2.0 |
Cell Cycle/*genetics | 2 | 2.0 |
Green Fluorescent Proteins | 9 | 1.0 |
Culture Techniques | 4 | 0.0 |
DNA Probes | 6 | 0.0 |
DNA, Complementary/isolation & purification | 3 | 1.0 |
Estradiol/pharmacology | 4 | 1.0 |
Hydrocortisone/pharmacology | 2 | 2.0 |
Progesterone/pharmacology | 2 | 1.0 |
DNA, Neoplasm | 7 | 6.0 |
Neoplasm Invasiveness | 17 | 1.0 |
Cell Transformation, Neoplastic/genetics/pathology | 3 | 14.0 |
Gene Expression Regulation, Neoplastic/genetics | 5 | 2.0 |
Karyotyping | 10 | 0.0 |
Prostatic Neoplasms/*genetics/pathology | 5 | 6.0 |
Translocation, Genetic | 2 | 0.0 |
Catalytic Domain | 2 | 0.0 |
Phosphorylation/radiation effects | 5 | 16.0 |
Substrate Specificity | 11 | 0.0 |
X-Rays | 3 | 2.0 |
Double-Blind Method | 4 | 0.0 |
Receptors, Estrogen | 2 | 11.0 |
*Oligonucleotide Array Sequence Analysis | 3 | 1.0 |
*Signal Transduction | 10 | 0.0 |
Chromatin/metabolism | 6 | 2.0 |
Adenocarcinoma/genetics/pathology | 4 | 9.0 |
Tumor Cells, Cultured/drug effects | 2 | 0.0 |
DNA-Binding Proteins/*chemistry/*metabolism | 2 | 3.0 |
Protein Structure, Quaternary | 2 | 1.0 |
Protein Structure, Secondary | 6 | 0.0 |
Chromosomes, Human, Pair 4/*genetics | 2 | 2.0 |
Contig Mapping | 2 | 1.0 |
Expressed Sequence Tags | 2 | 0.0 |
*Sequence Homology, Nucleic Acid | 3 | 4.0 |
Breast Neoplasms/epidemiology/*genetics/*prevention & control | 4 | 100.0 |
*Mastectomy | 19 | 90.0 |
Life Style | 8 | 6.0 |
China/epidemiology | 2 | 1.0 |
Genetic Screening/*standards | 2 | 66.0 |
*Practice Guidelines | 3 | 11.0 |
Breast Neoplasms/genetics/*prevention & control | 10 | 90.0 |
Chemoprevention | 3 | 7.0 |
Chickens | 2 | 0.0 |
*Chromosomes, Human, Pair 11 | 3 | 0.0 |
*Gene Silencing | 5 | 2.0 |
Cell Cycle Proteins/*genetics | 4 | 2.0 |
DNA-Binding Proteins/genetics | 10 | 1.0 |
Microsatellite Repeats/genetics | 15 | 3.0 |
Protein Kinases/*genetics | 6 | 5.0 |
Stomach Neoplasms/*genetics | 3 | 2.0 |
Apoptosis/physiology | 7 | 2.0 |
Cell Division/physiology | 2 | 0.0 |
Okadaic Acid/pharmacology | 2 | 2.0 |
Peptide Fragments/genetics/metabolism | 3 | 2.0 |
Phosphoprotein Phosphatase/antagonists & inhibitors | 2 | 6.0 |
Phosphorylation/drug effects | 2 | 0.0 |
Antibodies, Monoclonal | 5 | 0.0 |
DNA/metabolism/radiation effects | 2 | 20.0 |
*DNA Damage/genetics | 2 | 100.0 |
Protein p53/*genetics/metabolism | 2 | 5.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/genetics | 7 | 16.0 |
BRCA1 Protein/chemistry/genetics/*metabolism | 11 | 100.0 |
DNA Ligases/chemistry/*metabolism | 2 | 100.0 |
DNA-Binding Proteins/chemistry/*metabolism | 3 | 1.0 |
Magnetic Resonance Spectroscopy | 5 | 0.0 |
Protein Binding/genetics | 5 | 2.0 |
Histones/*metabolism | 4 | 3.0 |
*Cell Differentiation | 2 | 0.0 |
*Gene Expression | 7 | 0.0 |
Keratin/analysis | 5 | 2.0 |
Protein p53/analysis | 3 | 1.0 |
Contraceptives, Oral/*therapeutic use | 4 | 57.0 |
*Heterozygote Detection | 13 | 11.0 |
*RNA Splice Sites | 2 | 22.0 |
Epidemiology, Molecular | 7 | 7.0 |
Gene Expression Regulation/*physiology | 4 | 1.0 |
Promoter Regions (Genetics)/genetics | 12 | 1.0 |
RNA Polymerase II/metabolism | 3 | 2.0 |
RNA, Small Interfering/genetics/metabolism | 2 | 4.0 |
Receptors, Estrogen/genetics/*metabolism | 3 | 8.0 |
Transcription Factors/*metabolism | 15 | 0.0 |
Carrier Proteins | 2 | 3.0 |
DNA Damage/physiology | 5 | 19.0 |
DNA-Binding Proteins/physiology | 3 | 1.0 |
Phosphoproteins | 2 | 25.0 |
RNA, Small Interfering/genetics | 4 | 3.0 |
Telomere/*physiology | 2 | 28.0 |
BRCA1 Protein/analysis/*genetics | 3 | 100.0 |
Gene Expression Regulation, Neoplastic/physiology | 8 | 5.0 |
Tumor Markers, Biological/analysis/*genetics | 2 | 9.0 |
Carrier Proteins/chemistry/genetics/*metabolism | 3 | 2.0 |
Cyclins/*metabolism | 3 | 1.0 |
Cytoplasm/metabolism | 7 | 0.0 |
Nuclear Localization Signal | 3 | 4.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 6 | 1.0 |
*Attitude | 2 | 20.0 |
*Breast Neoplasms | 3 | 15.0 |
Data Collection | 6 | 7.0 |
Stress, Psychological | 2 | 7.0 |
Antineoplastic Agents/*pharmacology | 8 | 0.0 |
Drug Resistance, Neoplasm | 4 | 0.0 |
Microtubules/*drug effects | 2 | 10.0 |
Mitogen-Activated Protein Kinase 8 | 2 | 2.0 |
Mitotic Spindle Apparatus/drug effects | 2 | 33.0 |
Paclitaxel/pharmacology | 6 | 6.0 |
RNA, Messenger/drug effects | 2 | 3.0 |
Vincristine/pharmacology | 3 | 5.0 |
Neoplasms, Multiple Primary/*genetics | 7 | 17.0 |
*Chromosomes, Human, Pair 15 | 2 | 0.0 |
Netherlands/epidemiology | 10 | 9.0 |
Polymorphism, Restriction Fragment Length | 10 | 0.0 |
Ovarian Neoplasms/genetics/*pathology | 4 | 18.0 |
Antineoplastic Agents, Phytogenic/pharmacology | 3 | 3.0 |
Breast Neoplasms/drug therapy | 2 | 6.0 |
Cell Cycle/*drug effects | 2 | 1.0 |
Cisplatin/pharmacology | 4 | 2.0 |
DNA Damage/drug effects | 3 | 6.0 |
DNA, Complementary | 18 | 0.0 |
Ataxia Telangiectasia | 3 | 30.0 |
Protein Kinases/metabolism | 9 | 2.0 |
Genes, p53 | 26 | 5.0 |
Mice, Knockout | 26 | 1.0 |
Genes, BRCA1/*genetics | 218 | 98.0 |
Breast Neoplasms/genetics/*psychology | 7 | 100.0 |
Socioeconomic Factors | 6 | 3.0 |
Adenomatous Polyposis Coli Protein/genetics | 2 | 12.0 |
Cadherins/genetics | 3 | 5.0 |
Colonic Neoplasms/genetics | 5 | 8.0 |
Genes, BRCA1/genetics | 58 | 85.0 |
*Genetic Techniques | 3 | 4.0 |
Saccharomyces cerevisiae/*genetics | 2 | 1.0 |
Breast/pathology | 5 | 17.0 |
*Molecular Biology | 3 | 8.0 |
Tumor Markers, Biological/analysis | 8 | 1.0 |
Hydrolysis | 5 | 0.0 |
BRCA2 Protein | 390 | 77.0 |
Finland/epidemiology | 8 | 7.0 |
Transcription Factors/*genetics | 309 | 16.0 |
Apoptosis/drug effects | 8 | 1.0 |
*CDC2-CDC28 Kinases | 3 | 0.0 |
Cell Cycle/drug effects | 5 | 0.0 |
Cyclin-Dependent Kinases/metabolism | 4 | 1.0 |
Cyclins/metabolism | 3 | 0.0 |
Cysteine Endopeptidases/*metabolism | 3 | 1.0 |
Cysteine Proteinase Inhibitors/pharmacology | 2 | 0.0 |
Leupeptins/pharmacology | 3 | 2.0 |
Multienzyme Complexes/antagonists & inhibitors/*metabolism | 2 | 9.0 |
Poly(ADP-ribose) Polymerases/metabolism | 2 | 1.0 |
Proteasome Endopeptidase Complex | 5 | 0.0 |
Protein p53/metabolism | 19 | 3.0 |
Genes, p53/genetics | 20 | 9.0 |
*Mice, Knockout | 2 | 15.0 |
Protein-Serine-Threonine Kinases/genetics | 9 | 7.0 |
Child, Preschool | 10 | 0.0 |
Infant | 10 | 0.0 |
Transcription Factors/genetics | 103 | 12.0 |
Neoplasm Proteins | 2 | 6.0 |
Precancerous Conditions | 2 | 11.0 |
Genetic Markers/*genetics | 7 | 6.0 |
Breast/metabolism | 13 | 14.0 |
Carcinoma/genetics | 4 | 12.0 |
Chromosome Aberrations | 16 | 2.0 |
Genes, erbB-2/genetics | 3 | 11.0 |
RNA/metabolism | 3 | 0.0 |
Polymorphism, Genetic/*genetics | 6 | 0.0 |
Colorectal Neoplasms/genetics | 3 | 7.0 |
*Primary Health Care | 2 | 20.0 |
*CpG Islands | 6 | 7.0 |
Luciferases/metabolism | 3 | 0.0 |
Israel | 13 | 8.0 |
Neoplasm Proteins/genetics | 105 | 21.0 |
Breast Neoplasms/epidemiology/*genetics/pathology | 4 | 50.0 |
Prostatic Neoplasms/genetics | 9 | 20.0 |
Spectrometry, Mass, Electrospray Ionization | 2 | 2.0 |
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 0.0 |
BRCA1 Protein/*physiology | 21 | 100.0 |
Carrier Proteins/genetics/metabolism | 3 | 1.0 |
Genes, Retinoblastoma | 3 | 3.0 |
Retinoblastoma Protein/*metabolism | 3 | 1.0 |
Decision Making | 17 | 24.0 |
Nuclear Family | 6 | 2.0 |
Practice Guidelines | 5 | 6.0 |
Apoptosis/genetics | 4 | 1.0 |
BRCA1 Protein/physiology | 4 | 26.0 |
DNA Repair/genetics | 11 | 6.0 |
BRCA1 Protein/*biosynthesis | 11 | 100.0 |
Breast/cytology/metabolism | 4 | 18.0 |
Carcinoma, Ductal, Breast/genetics/*metabolism/pathology | 2 | 28.0 |
Neoplasm Proteins/*biosynthesis/genetics | 2 | 1.0 |
*Transcription Factors | 12 | 0.0 |
Biometry | 2 | 13.0 |
District of Columbia/epidemiology | 3 | 33.0 |
Epidemiologic Methods | 3 | 5.0 |
Likelihood Functions | 13 | 7.0 |
Models, Statistical | 5 | 2.0 |
Cell Adhesion | 3 | 0.0 |
Cell Movement | 2 | 0.0 |
DNA, Complementary/analysis | 2 | 0.0 |
*Gene Expression Regulation | 12 | 0.0 |
Breast Neoplasms/*genetics/physiopathology | 2 | 28.0 |
Genetic Markers/genetics | 26 | 5.0 |
Protein-Serine-Threonine Kinases/*genetics | 17 | 5.0 |
Genes, Tumor Suppressor/*genetics | 44 | 14.0 |
*Population Surveillance | 4 | 11.0 |
Signal Transduction/genetics | 3 | 1.0 |
*Endodeoxyribonucleases | 2 | 7.0 |
*Exodeoxyribonucleases | 2 | 8.0 |
Fungal Proteins/metabolism | 4 | 2.0 |
Genome | 4 | 1.0 |
Penetrance | 17 | 14.0 |
Carrier Proteins/metabolism | 9 | 1.0 |
Genes, Tumor Suppressor/genetics | 12 | 7.0 |
*Genetic Predisposition to Disease/genetics | 2 | 28.0 |
*Mammography | 5 | 45.0 |
Disease Susceptibility | 38 | 5.0 |
Neoplasm Proteins/genetics/*metabolism | 5 | 2.0 |
Cell-Free System | 2 | 0.0 |
Recombinant Fusion Proteins/biosynthesis/genetics | 2 | 2.0 |
BRCA1 Protein/biosynthesis/*genetics | 8 | 100.0 |
Cyclins/genetics/metabolism | 2 | 3.0 |
Estrogens | 4 | 17.0 |
Histone Deacetylases/metabolism | 3 | 3.0 |
Genes, erbB-2 | 8 | 10.0 |
S Phase/physiology | 7 | 9.0 |
DNA, Neoplasm/genetics/isolation & purification | 2 | 1.0 |
Ovarian Neoplasms/genetics/*prevention & control | 8 | 100.0 |
Breast Neoplasms/*metabolism/pathology | 4 | 2.0 |
*BRCA2 Protein | 3 | 100.0 |
Chickens/*genetics | 2 | 2.0 |
Anxiety | 2 | 14.0 |
Breast Neoplasms/diagnosis/*genetics/psychology | 5 | 83.0 |
Depression | 3 | 27.0 |
Ovarian Neoplasms/diagnosis/*genetics/psychology | 3 | 100.0 |
Truth Disclosure | 2 | 28.0 |
Breast Neoplasms/genetics/*prevention & control/surgery | 3 | 100.0 |
*Mastectomy, Simple | 2 | 100.0 |
Breast Neoplasms/epidemiology/genetics/*prevention & control/surgery | 2 | 100.0 |
Ethnic Groups/genetics | 6 | 3.0 |
Canada/epidemiology | 4 | 10.0 |
Carcinoma, Ductal, Breast/epidemiology/*genetics/pathology | 2 | 100.0 |
Carcinoma, Lobular/epidemiology/*genetics/pathology | 2 | 100.0 |
Netherlands | 8 | 5.0 |
Genes, Dominant/genetics | 3 | 2.0 |
Population Surveillance | 10 | 6.0 |
Chromosomes, Human, Pair 3/*genetics | 2 | 0.0 |
Genome, Human | 3 | 0.0 |
Receptors, Androgen/*genetics | 2 | 1.0 |
Repetitive Sequences, Nucleic Acid | 12 | 1.0 |
Breast Neoplasms/*genetics/*mortality/pathology | 2 | 100.0 |
Italy/epidemiology | 4 | 1.0 |
Neoplasm Proteins/*physiology | 3 | 3.0 |
Transcription Factors/*physiology | 5 | 1.0 |
Finland | 9 | 3.0 |
*Jews | 10 | 23.0 |
Parity | 5 | 4.0 |
DNA, Neoplasm/*analysis | 11 | 5.0 |
Electrophoresis, Polyacrylamide Gel/*methods | 3 | 10.0 |
Breast Neoplasms/*genetics/*metabolism | 4 | 10.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Cell Transformation, Neoplastic/genetics | 12 | 4.0 |
Cell Cycle/*physiology | 9 | 3.0 |
Transcription Factors/genetics/*physiology | 8 | 4.0 |
Microscopy, Electron | 5 | 0.0 |
Tumor Stem Cell Assay | 2 | 1.0 |
Adenoma/*genetics/pathology | 2 | 7.0 |
Cell Cycle Proteins/genetics | 5 | 5.0 |
Chromosome Disorders | 7 | 2.0 |
Cyclin-Dependent Kinases/antagonists & inhibitors | 2 | 2.0 |
Neoplastic Syndromes, Hereditary/genetics | 16 | 53.0 |
Receptors, Estrogen/biosynthesis | 2 | 4.0 |
DNA, Complementary/chemistry/genetics | 5 | 1.0 |
Mice, Inbred Strains | 4 | 0.0 |
Testis/metabolism | 4 | 1.0 |
Tissue Distribution | 7 | 0.0 |
BRCA1 Protein/chemistry/physiology | 2 | 100.0 |
Chromosomes, Human, Pair 13/genetics | 7 | 10.0 |
Prostatic Neoplasms/epidemiology/*genetics/pathology | 2 | 50.0 |
Biological Markers | 4 | 0.0 |
Transcription Factors/genetics/*metabolism | 6 | 0.0 |
*Adaptation, Psychological | 2 | 6.0 |
Point Mutation/genetics | 5 | 2.0 |
Severity of Illness Index | 3 | 0.0 |
Gene Order | 3 | 7.0 |
Mutagenesis, Insertional | 9 | 3.0 |
*Case-Control Studies | 2 | 22.0 |
Research Design/standards | 2 | 22.0 |
Neoplasms/*therapy | 2 | 1.0 |
DNA Polymerase II/metabolism | 2 | 11.0 |
Drosophila | 3 | 0.0 |
Fungal Proteins/chemistry | 2 | 7.0 |
Schizosaccharomyces/metabolism | 3 | 17.0 |
*Schizosaccharomyces pombe Proteins | 2 | 2.0 |
*Transglutaminases | 2 | 33.0 |
BRCA1 Protein/antagonists & inhibitors/*metabolism | 2 | 100.0 |
Protein Binding/physiology | 3 | 1.0 |
Protein Structure, Tertiary/physiology | 2 | 1.0 |
Recombinant Fusion Proteins/genetics/metabolism | 12 | 1.0 |
Neoplasms/genetics | 9 | 7.0 |
Haplotypes | 34 | 1.0 |
Gene Expression Regulation, Developmental/physiology | 2 | 2.0 |
*Neoplasm Proteins | 8 | 1.0 |
*Tumor Markers, Biological | 2 | 1.0 |
*Recombination, Genetic | 7 | 2.0 |
Antibody Specificity | 8 | 0.0 |
BRCA1 Protein/immunology/*metabolism | 3 | 100.0 |
Neoplastic Syndromes, Hereditary/*genetics/metabolism/pathology | 2 | 100.0 |
Israel/epidemiology | 10 | 24.0 |
Exodeoxyribonucleases/*metabolism | 2 | 14.0 |
Holoenzymes/metabolism | 2 | 40.0 |
Ubiquitins/metabolism | 3 | 2.0 |
BRCA1 Protein/genetics/immunology/metabolism | 2 | 100.0 |
Monte Carlo Method | 2 | 2.0 |
Protein Structure, Secondary/genetics | 2 | 11.0 |
Protein p53/chemistry/genetics/metabolism | 2 | 40.0 |
Costs and Cost Analysis | 2 | 3.0 |
Genetic Predisposition to Disease/*ethnology | 6 | 50.0 |
Peptide Fragments/chemistry/genetics/metabolism | 2 | 2.0 |
Breast Neoplasms/*genetics/prevention & control/*surgery | 2 | 100.0 |
*Gene Deletion | 20 | 2.0 |
Nuclear Proteins/*genetics | 3 | 0.0 |
Anxiety/psychology | 3 | 25.0 |
*Health Behavior | 2 | 15.0 |
Norway/epidemiology | 6 | 21.0 |
Carcinoma/genetics/pathology | 2 | 9.0 |
Cell Cycle/*genetics/physiology | 2 | 40.0 |
DNA Restriction Enzymes/metabolism | 2 | 2.0 |
Transduction, Genetic | 2 | 0.0 |
Breast Neoplasms, Male/epidemiology/genetics | 9 | 81.0 |
Ethics, Medical | 7 | 38.0 |
Breast Neoplasms/*genetics/radiotherapy/surgery | 2 | 100.0 |
Computer Simulation | 5 | 1.0 |
Ovary/*surgery | 2 | 40.0 |
Disease Models, Animal | 12 | 0.0 |
Receptors, Progesterone/*metabolism | 2 | 1.0 |
Cell Proliferation/drug effects | 2 | 2.0 |
Cyclin D1/metabolism | 2 | 1.0 |
Retinoblastoma Protein/metabolism | 3 | 0.0 |
BRCA1 Protein/*chemistry/genetics/*metabolism | 3 | 100.0 |
Cell Cycle/radiation effects | 2 | 7.0 |
DNA-Binding Proteins | 4 | 4.0 |
Introns/*genetics | 3 | 1.0 |
Mitogen-Activated Protein Kinases/metabolism | 2 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 2 | 0.0 |
Response Elements | 2 | 0.0 |
Nuclear Proteins/physiology | 2 | 2.0 |
Linkage (Genetics)/*genetics | 5 | 1.0 |
BRCA1 Protein/biosynthesis | 5 | 83.0 |
Cycloheximide/pharmacology | 5 | 0.0 |
Protein Synthesis Inhibitors/pharmacology | 3 | 0.0 |
Protein p53/*physiology | 2 | 1.0 |
Binding Sites/physiology | 2 | 1.0 |
Neoplasm Proteins/biosynthesis/*genetics | 8 | 8.0 |
Ovarian Neoplasms/*metabolism | 2 | 3.0 |
Protein p53/*metabolism | 8 | 1.0 |
Transcription Factors/biosynthesis/*genetics | 7 | 6.0 |
Tumor Cells, Cultured/drug effects/radiation effects | 3 | 16.0 |
Arylamine N-Acetyltransferase/genetics | 3 | 5.0 |
Cytochrome P-450 CYP1A1/genetics | 3 | 3.0 |
Environmental Exposure | 2 | 1.0 |
France/ethnology | 4 | 10.0 |
Glutathione Transferase/genetics | 7 | 2.0 |
Isoenzymes/genetics | 2 | 0.0 |
Breast Neoplasms/epidemiology/*genetics/mortality | 2 | 100.0 |
Artifacts | 2 | 3.0 |
Gene Duplication | 3 | 1.0 |
Lymphocytes/chemistry | 4 | 6.0 |
Nuclear Proteins/chemistry/genetics | 2 | 18.0 |
Zinc Fingers | 15 | 2.0 |
Bioethics | 3 | 50.0 |
Colorado | 2 | 13.0 |
*Family Practice | 2 | 33.0 |
*Physician's Practice Patterns | 2 | 11.0 |
Carcinoma, Endometrioid/genetics/pathology | 2 | 50.0 |
Fallopian Tube Neoplasms/epidemiology/*genetics | 2 | 100.0 |
Bloom Syndrome/genetics | 3 | 23.0 |
Multigene Family | 5 | 0.0 |
Neoplasms/*enzymology/*genetics | 2 | 16.0 |
Chromosomes/ultrastructure | 3 | 10.0 |
Proto-Oncogene Proteins/genetics | 10 | 1.0 |
Recombinant Fusion Proteins | 2 | 0.0 |
Transcription Factors/metabolism | 12 | 0.0 |
Yeasts/genetics | 2 | 2.0 |
Breast Neoplasms/blood/*genetics | 3 | 42.0 |
Microsatellite Repeats/*genetics | 5 | 1.0 |
Iceland/epidemiology | 4 | 28.0 |
Prostatic Neoplasms/epidemiology/genetics | 3 | 75.0 |
Rec A Recombinases/genetics | 2 | 40.0 |
Retinoblastoma Protein/genetics | 2 | 5.0 |
Gene Therapy/*methods | 2 | 0.0 |
Neoplasm Proteins/genetics/*physiology | 8 | 16.0 |
Cyclins/analysis | 2 | 4.0 |
Receptors, Estrogen/analysis | 11 | 3.0 |
Precancerous Conditions/genetics/pathology | 4 | 22.0 |
*Cell Transformation, Neoplastic | 8 | 1.0 |
Protein Kinases/genetics | 2 | 3.0 |
Iran | 2 | 5.0 |
Sequence Homology, Nucleic Acid | 8 | 0.0 |
Women's Health | 6 | 17.0 |
*Polymorphism, Single Nucleotide | 3 | 0.0 |
BRCA1 Protein/deficiency/genetics | 2 | 100.0 |
DNA/chemistry/metabolism | 2 | 2.0 |
Genes, myc | 7 | 2.0 |
Binding Sites/genetics | 3 | 0.0 |
Genes, BRCA1/genetics/*physiology | 2 | 100.0 |
DNA, Neoplasm/genetics/metabolism | 6 | 7.0 |
RNA, Messenger/genetics | 16 | 0.0 |
Fanconi Anemia/*genetics/metabolism | 3 | 37.0 |
Carcinoma/*genetics/metabolism | 3 | 10.0 |
Forecasting | 10 | 3.0 |
*Models, Statistical | 4 | 6.0 |
Breast Neoplasms/*genetics/mortality/pathology | 4 | 50.0 |
Gene Frequency/genetics | 11 | 2.0 |
Sequence Deletion/genetics | 4 | 2.0 |
Antioxidants/*metabolism | 3 | 3.0 |
Diet | 3 | 0.0 |
Oxidative Stress | 5 | 1.0 |
Tumor Markers, Biological/genetics | 7 | 7.0 |
DNA Fingerprinting/methods | 2 | 3.0 |
*DNA Repair Enzymes | 8 | 8.0 |
Androstadienes/pharmacology | 2 | 0.0 |
BRCA1 Protein/*deficiency | 3 | 100.0 |
Pancreatic Neoplasms/genetics/metabolism | 2 | 50.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors | 2 | 2.0 |
Breast Neoplasms/diagnosis/epidemiology/*genetics | 5 | 100.0 |
Algorithms | 9 | 2.0 |
DNA, Neoplasm/analysis/genetics | 3 | 3.0 |
Breast Neoplasms, Male/*genetics | 16 | 57.0 |
Health Surveys | 5 | 7.0 |
*Patient Compliance | 2 | 4.0 |
Epidemiologic Studies | 2 | 4.0 |
Linkage Disequilibrium | 4 | 0.0 |
RNA Splicing | 9 | 1.0 |
Neoplasms/*epidemiology/genetics | 2 | 100.0 |
Ontario | 4 | 17.0 |
Base Pair Mismatch | 2 | 1.0 |
Luminescent Proteins/genetics | 2 | 1.0 |
Molecular Biology/*methods | 2 | 8.0 |
*Variation (Genetics) | 11 | 1.0 |
Sex Distribution | 3 | 1.0 |
Radiation Tolerance | 3 | 3.0 |
Radiotherapy Dosage | 4 | 2.0 |
Cyclins/*genetics | 4 | 2.0 |
Caffeine/pharmacology | 2 | 2.0 |
Hydrogen Peroxide/pharmacology | 3 | 1.0 |
Prostatic Neoplasms/*genetics | 13 | 7.0 |
Sequence Tagged Sites | 4 | 1.0 |
*Disease Models, Animal | 3 | 0.0 |
Embryo Loss/*genetics | 2 | 40.0 |
Gene Transfer Techniques | 6 | 1.0 |
Genomic Library | 2 | 0.0 |
Trans-Activators/genetics/*metabolism | 2 | 0.0 |
G1 Phase | 4 | 1.0 |
Protein Isoforms/genetics | 2 | 0.0 |
Electrophoresis/methods | 2 | 2.0 |
Diseases in Twins/*genetics | 2 | 7.0 |
BRCA1 Protein/*genetics/physiology | 6 | 100.0 |
Dogs | 7 | 0.0 |
Recombinant Fusion Proteins/genetics | 3 | 1.0 |
Trans-Activation (Genetics)/genetics | 2 | 2.0 |
*Attitude to Health | 8 | 24.0 |
Health Knowledge, Attitudes, Practice | 7 | 21.0 |
Quality of Life | 3 | 1.0 |
Chromosome Segregation | 2 | 5.0 |
Calpain/metabolism | 2 | 8.0 |
Cell Fractionation | 2 | 0.0 |
Carcinoma/metabolism | 2 | 3.0 |
Neoplasms/*metabolism | 2 | 2.0 |
*RNA-Binding Proteins | 2 | 0.0 |
Breast/*chemistry | 2 | 8.0 |
Breast Neoplasms/*chemistry | 2 | 2.0 |
Culture Media | 3 | 0.0 |
*Zinc Fingers | 3 | 1.0 |
Genetic Counseling/*psychology | 5 | 83.0 |
Ovarian Neoplasms/genetics/*psychology | 5 | 100.0 |
Breast Neoplasms/*diagnosis/genetics/psychology | 4 | 100.0 |
Pilot Projects | 4 | 0.0 |
Poland/epidemiology | 6 | 10.0 |
BRCA1 Protein/chemistry/genetics | 2 | 100.0 |
Nuclear Proteins/chemistry | 2 | 7.0 |
Estrogens/pharmacology | 2 | 2.0 |
*Gene Expression Regulation/drug effects | 4 | 2.0 |
Genes, Reporter/genetics | 3 | 1.0 |
Genetic Vectors/genetics | 3 | 1.0 |
Retroviridae/genetics | 3 | 0.0 |
Statistics | 2 | 0.0 |
Alu Elements | 2 | 8.0 |
DNA Primers/genetics | 14 | 1.0 |
Gene Rearrangement | 6 | 1.0 |
Breast Neoplasms/*genetics/pathology/therapy | 3 | 50.0 |
Protein-Serine-Threonine Kinases/genetics/*metabolism | 5 | 2.0 |
Rabbits | 10 | 0.0 |
Serine/metabolism | 4 | 1.0 |
Breast/*surgery | 2 | 66.0 |
Down-Regulation/drug effects | 4 | 1.0 |
Estrogen Antagonists/*pharmacology | 2 | 2.0 |
Gene Expression Regulation, Neoplastic/drug effects | 4 | 0.0 |
Genes, BRCA1/drug effects | 2 | 66.0 |
Transcription, Genetic/drug effects | 4 | 0.0 |
Ovarian Neoplasms/*genetics/pathology/surgery | 2 | 50.0 |
Environment | 2 | 2.0 |
Cell Division/drug effects/genetics | 3 | 3.0 |
Counseling | 5 | 22.0 |
Primary Prevention | 2 | 16.0 |
Adenosine Triphosphate/metabolism | 2 | 0.0 |
Decision Support Techniques | 4 | 22.0 |
Patient Satisfaction | 3 | 7.0 |
Italy | 9 | 1.0 |
Communication | 4 | 20.0 |
Europe/epidemiology | 4 | 4.0 |
BRCA1 Protein/*genetics/*physiology | 2 | 100.0 |
Cross-Linking Reagents/pharmacology | 3 | 2.0 |
Cell Cycle Proteins/metabolism/*physiology | 2 | 13.0 |
Nuclear Proteins/metabolism/*physiology | 2 | 6.0 |
DNA/biosynthesis | 3 | 0.0 |
Patient Compliance | 2 | 1.0 |
Prejudice | 5 | 33.0 |
Breast Neoplasms/*metabolism/*pathology | 2 | 5.0 |
Mammaplasty | 3 | 42.0 |
Signal Transduction/*physiology | 2 | 0.0 |
Trans-Activation (Genetics)/drug effects/physiology | 2 | 10.0 |
Sequence Analysis, DNA/methods | 2 | 2.0 |
Ovarian Neoplasms/genetics/*therapy | 2 | 100.0 |
Breast Neoplasms/prevention & control | 2 | 25.0 |
Evaluation Studies | 6 | 0.0 |
Genetic Screening/psychology | 5 | 100.0 |
Ovarian Neoplasms/prevention & control | 2 | 66.0 |
Breast Neoplasms/*genetics/radiotherapy | 2 | 100.0 |
*Cell Cycle | 9 | 4.0 |
Molecular Weight | 7 | 0.0 |
BRCA1 Protein/*chemistry/physiology | 5 | 100.0 |
Breast Neoplasms/etiology | 2 | 22.0 |
Emotions | 4 | 18.0 |
Europe/ethnology | 11 | 12.0 |
Health Behavior | 3 | 17.0 |
Social Support | 2 | 4.0 |
RNA Polymerase II/*metabolism | 5 | 5.0 |
Breast Neoplasms/etiology/*genetics/pathology | 2 | 100.0 |
Receptors, Estrogen/physiology | 2 | 7.0 |
Breast Neoplasms/epidemiology/etiology/*genetics | 3 | 42.0 |
Oligonucleotides, Antisense/pharmacology | 3 | 1.0 |
Up-Regulation/drug effects | 3 | 0.0 |
Neoplasm Proteins/*genetics/metabolism | 4 | 2.0 |
Transcription Factors/*genetics/metabolism | 4 | 1.0 |
DNA Repair/genetics/*physiology | 2 | 9.0 |
Neoplasm Proteins/deficiency/genetics/*physiology | 2 | 40.0 |
Transcription Factors/deficiency/genetics/*physiology | 2 | 11.0 |
Gene Silencing/physiology | 4 | 16.0 |
Ovarian Neoplasms/*genetics/metabolism/pathology | 3 | 10.0 |
BRCA1 Protein/analysis/genetics | 5 | 100.0 |
DNA/analysis/genetics | 3 | 2.0 |
Neoplasm Proteins/analysis/*genetics | 5 | 16.0 |
Transcription Factors/analysis/*genetics | 3 | 9.0 |
African Americans | 2 | 1.0 |
African Continental Ancestry Group/*genetics | 4 | 1.0 |
*Chromosomes, Human, Pair 8 | 2 | 0.0 |
DNA/blood | 5 | 3.0 |
Carcinoma in Situ/genetics/pathology | 3 | 42.0 |
Carcinoma, Ductal, Breast/genetics/pathology | 3 | 27.0 |
Cell Nucleus/pathology | 2 | 2.0 |
Receptors, Progesterone/analysis | 5 | 2.0 |
Receptor, IGF Type 1/*genetics | 3 | 12.0 |
Somatomedins/metabolism | 2 | 6.0 |
Fluorescent Dyes | 2 | 0.0 |
Neoplasm Proteins/analysis/genetics | 4 | 16.0 |
Transcription Factors/analysis/genetics | 4 | 28.0 |
Greece/epidemiology | 2 | 5.0 |
Turkey/ethnology | 3 | 9.0 |
*Introns | 5 | 2.0 |
False Negative Reactions | 4 | 2.0 |
Gene Rearrangement/genetics | 2 | 4.0 |
Genetic Techniques | 4 | 4.0 |
Cell Compartmentation | 6 | 1.0 |
DNA, Neoplasm/blood/genetics | 4 | 40.0 |
BRCA1 Protein/biosynthesis/genetics | 4 | 100.0 |
*Pregnancy | 2 | 1.0 |
*Gene Transfer Techniques | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/*genetics | 7 | 3.0 |
Protein p53/physiology | 3 | 3.0 |
Recombinant Fusion Proteins/biosynthesis | 5 | 1.0 |
Infant, Newborn | 2 | 0.0 |
Mothers | 2 | 2.0 |
Neoplasms/epidemiology/*genetics | 3 | 37.0 |
Neoplasms, Second Primary/epidemiology/*genetics | 2 | 100.0 |
Neoplasm Transplantation | 4 | 0.0 |
Protein p53/biosynthesis/genetics | 3 | 6.0 |
Proto-Oncogene Proteins/biosynthesis/genetics | 2 | 2.0 |
Rats, Nude | 2 | 4.0 |
Gene Expression Regulation, Neoplastic/*radiation effects | 2 | 9.0 |
Half-Life | 3 | 0.0 |
Cell Nucleus/genetics/metabolism | 3 | 7.0 |
Carrier Proteins/*physiology | 2 | 0.0 |
Chromosome Aberrations/*genetics | 2 | 1.0 |
5-Methylcytosine | 2 | 9.0 |
Acetylation | 2 | 0.0 |
Breast Neoplasms/*genetics/*prevention & control/therapy | 2 | 100.0 |
*Genetics, Population | 6 | 1.0 |
Singapore/epidemiology | 2 | 6.0 |
Breast Neoplasms/*complications/*genetics | 2 | 100.0 |
*Gene Duplication | 4 | 2.0 |
Attitude | 2 | 6.0 |
Breast Neoplasms/*genetics/psychology | 8 | 88.0 |
*Decision Making | 6 | 66.0 |
Ovarian Neoplasms/*genetics/psychology | 4 | 80.0 |
Biopolymers | 2 | 1.0 |
Carrier Proteins/chemistry/physiology | 2 | 33.0 |
DNA Ligases/chemistry | 2 | 66.0 |
DNA-Binding Proteins/chemistry | 2 | 4.0 |
Polymorphism, Genetic/genetics | 7 | 1.0 |
Cell Survival/drug effects/radiation effects | 2 | 4.0 |
Genes, p16 | 2 | 2.0 |
Breast Neoplasms/*metabolism | 5 | 1.0 |
Chromatin/*metabolism | 2 | 1.0 |
Breast Neoplasms/*pathology | 4 | 1.0 |
Ovarian Neoplasms/*pathology | 2 | 3.0 |
*Genes, ras | 4 | 1.0 |
Receptor, erbB-2/metabolism | 6 | 3.0 |
ras Proteins/metabolism | 2 | 1.0 |
Breast Neoplasms/genetics/metabolism/pathology | 3 | 10.0 |
*Chromosomal Proteins, Non-Histone | 2 | 0.0 |
Gene Silencing/drug effects | 2 | 11.0 |
*Repressor Proteins | 3 | 0.0 |
Trans-Activation (Genetics)/drug effects | 2 | 0.0 |
Carcinoma, Ductal, Breast/genetics | 4 | 23.0 |
Carcinoma, Intraductal, Noninfiltrating/genetics | 2 | 33.0 |
Carcinoma, Lobular/genetics | 3 | 42.0 |
*Genome, Human | 5 | 1.0 |
*Gene Rearrangement | 5 | 2.0 |
Loss of Heterozygosity/genetics | 6 | 4.0 |
Ki-67 Antigen/analysis | 3 | 1.0 |
Ovarian Neoplasms/*genetics/mortality | 5 | 71.0 |
*Polymorphism, Single-Stranded Conformational | 7 | 5.0 |
Alcohol Drinking/adverse effects | 2 | 4.0 |
Radiotherapy/adverse effects | 2 | 5.0 |
Cross-Sectional Studies | 5 | 0.0 |
DNA Nucleotidylexotransferase/metabolism | 2 | 10.0 |
Luminescent Proteins/metabolism | 2 | 0.0 |
Breast Neoplasms/*genetics/prevention & control/surgery | 2 | 100.0 |
*Gene Expression Regulation, Neoplastic/drug effects | 2 | 3.0 |
Chemotherapy, Adjuvant | 4 | 1.0 |
DNA Damage/*genetics | 7 | 11.0 |
Proto-Oncogenes/genetics | 2 | 6.0 |
Smoking/adverse effects | 2 | 0.0 |
Carcinoma in Situ/*genetics/pathology | 2 | 13.0 |
Alcohol Drinking | 4 | 3.0 |
Cytoskeletal Proteins/genetics | 2 | 3.0 |
China | 6 | 1.0 |
Genetic Screening/*utilization | 3 | 100.0 |
*Health Knowledge, Attitudes, Practice | 4 | 14.0 |
North Carolina | 2 | 8.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 3 | 0.0 |
Adenosinetriphosphatase/*metabolism | 2 | 4.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
Biological Transport | 3 | 0.0 |
Sequence Analysis | 7 | 1.0 |
*Registries | 3 | 6.0 |
*Research Design | 3 | 25.0 |
Breast Neoplasms/*genetics/mortality | 2 | 40.0 |
Chromosomes, Artificial, Yeast | 11 | 2.0 |
DNA Damage/genetics/radiation effects | 2 | 25.0 |
DNA Repair/genetics/radiation effects | 2 | 25.0 |
Breast Neoplasms/diagnosis/genetics/*psychology | 4 | 100.0 |
Genetic Predisposition to Disease/*psychology | 3 | 100.0 |
Pseudogenes | 3 | 1.0 |
beta-Galactosidase/metabolism | 3 | 1.0 |
Carcinoma, Endometrioid/genetics | 2 | 28.0 |
Cystadenocarcinoma, Serous/genetics | 2 | 33.0 |
Neoplasms, Second Primary/genetics | 2 | 14.0 |
Surgical Procedures, Elective | 2 | 9.0 |
Aneuploidy | 7 | 3.0 |
Ovarian Neoplasms/chemistry/*genetics | 2 | 40.0 |
Endodeoxyribonucleases/metabolism | 3 | 9.0 |
Peptide Fragments/metabolism | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis/*methods | 8 | 6.0 |
*Genes, Dominant | 2 | 0.0 |
*Penetrance | 6 | 20.0 |
Ovarian Neoplasms/diagnosis/genetics/psychology | 3 | 100.0 |
Utah | 3 | 11.0 |
Hungary/epidemiology | 3 | 14.0 |
Breast Neoplasms/chemistry/*genetics | 3 | 16.0 |
Neoplasm Proteins/*analysis/genetics | 2 | 4.0 |
Down-Regulation/genetics | 2 | 3.0 |
Ovarian Neoplasms/enzymology/genetics | 2 | 28.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 2 | 0.0 |
BRCA1 Protein/*chemistry/genetics/metabolism | 4 | 100.0 |
Carrier Proteins/chemistry/metabolism | 2 | 6.0 |
*Patents | 4 | 100.0 |
Primary Prevention/methods | 2 | 28.0 |
Apoptosis/*physiology | 4 | 0.0 |
Rats, Wistar | 2 | 0.0 |
Fanconi Anemia/*complications/genetics/therapy | 2 | 100.0 |
Gene Therapy | 4 | 1.0 |
Histocompatibility Testing | 2 | 0.0 |
Leukemia, Myeloid/*complications/genetics/therapy | 2 | 100.0 |
Stem Cell Transplantation | 3 | 7.0 |
Adaptation, Psychological | 4 | 8.0 |
*Genetic Screening/psychology | 4 | 100.0 |
*Religion and Medicine | 2 | 66.0 |
Fluorescence | 3 | 1.0 |
*Gene Dosage | 3 | 3.0 |
Spodoptera | 2 | 0.0 |
Poland | 8 | 5.0 |
Adenosinetriphosphatase/metabolism | 2 | 1.0 |
DNA Helicases/metabolism | 2 | 7.0 |
Spectrum Analysis, Mass | 4 | 0.0 |
Oncogenes/*genetics | 2 | 2.0 |
Vaginal Smears | 2 | 3.0 |
Mutagenesis | 10 | 0.0 |
Arabs/genetics | 2 | 12.0 |
DNA/blood/genetics | 3 | 4.0 |
Immune Sera | 2 | 0.0 |
Nuclear Proteins/immunology/*metabolism | 3 | 33.0 |
Cell Nucleus/genetics | 2 | 6.0 |
DNA/*genetics | 2 | 0.0 |
Mice, SCID | 2 | 0.0 |
Methylation | 5 | 0.0 |
RNA | 2 | 4.0 |
Carcinoma, Lobular/genetics/pathology | 2 | 40.0 |
Carcinoma, Medullary/genetics/pathology | 2 | 50.0 |
Mitotic Index | 3 | 1.0 |
North America/epidemiology | 2 | 14.0 |
Fathers | 2 | 3.0 |
Prostatic Neoplasms/epidemiology/*genetics | 2 | 15.0 |
Protein Binding/radiation effects | 2 | 18.0 |
Cell Differentiation/genetics | 4 | 1.0 |
Cystadenocarcinoma, Serous/genetics/pathology | 2 | 66.0 |
Transcription Factor, Sp1/*metabolism | 2 | 0.0 |
Receptor, erbB-2/*genetics | 2 | 5.0 |
Amino Acid Sequence/genetics | 2 | 0.0 |
BRCA1 Protein/classification/*genetics | 2 | 100.0 |
Confidence Intervals | 4 | 1.0 |
Mutation, Missense/genetics | 5 | 2.0 |
Breast Neoplasms, Male/genetics/metabolism/pathology | 2 | 66.0 |
Sister Chromatid Exchange | 2 | 4.0 |
Breast Self-Examination | 5 | 100.0 |
Hyperplasia | 3 | 0.0 |
Nipples | 2 | 40.0 |
Adenocarcinoma, Clear Cell/genetics | 3 | 23.0 |
Polymorphism, Single Nucleotide | 3 | 0.0 |
Breast Neoplasms/*epidemiology/*genetics/pathology | 4 | 100.0 |
Linkage (Genetics)/genetics | 6 | 2.0 |
Genes, ras | 7 | 2.0 |
Neoplasms, Glandular and Epithelial/*genetics | 2 | 18.0 |
Protein p16/*genetics | 2 | 2.0 |
Exercise | 2 | 1.0 |
Poisson Distribution | 2 | 9.0 |
Markov Chains | 4 | 16.0 |
*Patient Participation | 2 | 50.0 |
Mastectomy/methods | 2 | 40.0 |
BRCA1 Protein/blood/*genetics | 2 | 100.0 |
Electrophoresis, Capillary/methods | 2 | 11.0 |
Neoplasm Proteins/blood/*genetics | 2 | 100.0 |
Transcription Factors/blood/*genetics | 2 | 66.0 |
*Carrier Proteins | 2 | 0.0 |
Protein p16/genetics | 3 | 3.0 |
Repressor Proteins/*genetics | 2 | 0.0 |
Skin/metabolism | 2 | 1.0 |
DNA, Neoplasm/chemistry | 3 | 13.0 |
Bone Neoplasms/pathology | 2 | 12.0 |
Osteosarcoma/pathology | 2 | 11.0 |
*Proto-Oncogene Proteins c-bcl-2 | 2 | 0.0 |
Chromatography, High Pressure Liquid/*methods | 3 | 2.0 |
Genetic Screening/economics/methods | 2 | 66.0 |
Nucleic Acid Heteroduplexes/genetics | 2 | 11.0 |
Nuclear Proteins/*chemistry | 2 | 8.0 |
*Risk | 3 | 33.0 |
Cell Nucleus/chemistry | 3 | 1.0 |
Frameshift Mutation/*genetics | 2 | 3.0 |
Retroviridae | 3 | 4.0 |
Health Personnel/*education | 2 | 22.0 |
Clinical Protocols | 2 | 3.0 |
Colorectal Neoplasms, Hereditary Nonpolyposis/*genetics | 3 | 3.0 |
Breast/cytology | 7 | 21.0 |
Breast Neoplasms, Male/genetics/pathology | 3 | 60.0 |
Carcinoma, Ductal, Breast/*genetics/pathology | 6 | 23.0 |
Embryo | 2 | 0.0 |
Breast Neoplasms, Male/diagnosis/*genetics | 2 | 100.0 |
Germany | 9 | 2.0 |
Fallopian Tube Neoplasms/*genetics/pathology | 2 | 100.0 |
*Family | 8 | 21.0 |
*RNA Splicing | 2 | 0.0 |
New York/epidemiology | 2 | 10.0 |
Cystic Fibrosis/genetics | 4 | 13.0 |
Gaucher Disease/genetics | 2 | 28.0 |
Genetic Diseases, Inborn/*genetics | 5 | 9.0 |
Cyclins/genetics | 6 | 4.0 |
DNA Topoisomerases, Type II/antagonists & inhibitors | 2 | 7.0 |
Etoposide/pharmacology | 4 | 2.0 |
Cysteine Endopeptidases/metabolism | 3 | 1.0 |
Multienzyme Complexes/metabolism | 2 | 1.0 |
*Receptors, Cytoplasmic and Nuclear | 2 | 2.0 |
Carcinoma, Lobular/*genetics | 3 | 42.0 |
*Polymerase Chain Reaction | 2 | 0.0 |
Belgium/epidemiology | 2 | 15.0 |
Endometrial Neoplasms/epidemiology/genetics | 2 | 66.0 |
Patient Care Team | 2 | 11.0 |
Program Evaluation | 2 | 4.0 |
*Mutagenesis, Insertional | 3 | 8.0 |
*DNA Mutational Analysis/methods | 2 | 40.0 |
*Decision Support Techniques | 4 | 26.0 |
Norway | 5 | 4.0 |
Matched-Pair Analysis | 2 | 2.0 |
Breast Neoplasms/enzymology/genetics | 5 | 29.0 |
Colorectal Neoplasms/enzymology/genetics | 2 | 33.0 |
Breast Neoplasms/diagnosis/*genetics/surgery | 2 | 100.0 |
Kidney Neoplasms/genetics | 2 | 2.0 |
Lymphocytes/radiation effects | 2 | 18.0 |
*DNA Helicases | 2 | 0.0 |
Templates, Genetic | 2 | 1.0 |
Repetitive Sequences, Nucleic Acid/*genetics | 3 | 2.0 |
Threonine/metabolism | 2 | 2.0 |
*Centrosome | 2 | 25.0 |
DNA, Satellite | 3 | 10.0 |
Micronuclei, Chromosome-Defective | 2 | 18.0 |
Mammary Neoplasms, Experimental/genetics | 4 | 44.0 |
RNA Helicases | 2 | 12.0 |
Receptors, Estrogen/*metabolism | 7 | 3.0 |
Ultracentrifugation | 3 | 1.0 |
Neoplasms/*genetics/*pathology | 2 | 25.0 |
Neoplasms, Experimental/genetics | 2 | 15.0 |
Antineoplastic Agents, Phytogenic/*pharmacology | 2 | 1.0 |
BRCA1 Protein/biosynthesis/genetics/*metabolism | 2 | 100.0 |
Paclitaxel/*pharmacology | 2 | 3.0 |
*Ubiquitin-Conjugating Enzymes | 3 | 4.0 |
DNA, Single-Stranded/metabolism | 2 | 3.0 |
RNA, Neoplasm/genetics | 5 | 1.0 |
Patient Acceptance of Health Care | 2 | 8.0 |
*Confidentiality | 2 | 100.0 |
*Family Health | 4 | 7.0 |
Parent-Child Relations | 2 | 20.0 |
*Truth Disclosure | 2 | 20.0 |
Lymphocytes/metabolism | 3 | 1.0 |
Breast Neoplasms/complications/*genetics | 5 | 100.0 |
Colorectal Neoplasms/epidemiology/*genetics | 2 | 15.0 |
DNA Replication/genetics | 3 | 5.0 |
Endometrial Neoplasms/*genetics | 3 | 6.0 |
Trans-Activation (Genetics)/*genetics | 2 | 2.0 |
Demography | 3 | 2.0 |
*Patient Acceptance of Health Care | 3 | 37.0 |
Breast Neoplasms/diagnosis/*genetics/*pathology | 2 | 100.0 |
Gene Amplification/genetics | 2 | 3.0 |
Precancerous Conditions/*genetics | 2 | 7.0 |
Gestational Age | 2 | 0.0 |
Li-Fraumeni Syndrome/*genetics | 2 | 11.0 |
Neoplasms/ethnology/*genetics | 2 | 66.0 |
Breast Neoplasms/ethnology/genetics | 5 | 100.0 |
Ovarian Neoplasms/ethnology/genetics | 4 | 100.0 |
Recombinant Fusion Proteins/biosynthesis/metabolism | 2 | 2.0 |
Serine/genetics/metabolism | 2 | 9.0 |
New York City | 2 | 6.0 |
Proliferating Cell Nuclear Antigen/metabolism | 4 | 1.0 |
Rats, Inbred Strains | 2 | 0.0 |
Estradiol/analogs & derivatives/pharmacology | 2 | 6.0 |
Estrogen Antagonists/pharmacology | 5 | 5.0 |
Receptors, Estrogen/*genetics/metabolism | 2 | 8.0 |
Recombinant Proteins/genetics/metabolism | 3 | 0.0 |
Cyclin E/metabolism | 2 | 1.0 |
Cyclin-Dependent Kinases/*metabolism | 2 | 0.0 |
Quality-Adjusted Life Years | 2 | 33.0 |
BRCA1 Protein/*analysis/genetics | 2 | 100.0 |
Neoplasm Metastasis | 5 | 0.0 |
Neoplasm Proteins/*genetics/physiology | 2 | 9.0 |
Transcription Factors/*genetics/physiology | 3 | 3.0 |
JNK Mitogen-Activated Protein Kinases | 2 | 0.0 |
Growth Substances/*biosynthesis | 2 | 4.0 |
Mammals/*genetics | 2 | 5.0 |
*Genes, BRCA1/physiology | 3 | 100.0 |
Breast Neoplasms/diagnosis/*genetics/prevention & control | 2 | 100.0 |
Quality of Health Care | 2 | 18.0 |
Breast Neoplasms/*metabolism/ultrastructure | 2 | 33.0 |
Neoplasm Proteins/*biosynthesis | 2 | 2.0 |
Transcription Factors/*biosynthesis | 2 | 1.0 |
Gene Expression Regulation, Neoplastic/*physiology | 3 | 1.0 |
Taiwan | 2 | 1.0 |
Embryo/cytology | 2 | 2.0 |
Suppression, Genetic | 2 | 3.0 |
Carrier Proteins/*genetics/metabolism | 2 | 0.0 |
Ovarian Neoplasms/diagnosis/*genetics/*prevention & control | 3 | 100.0 |
African Americans/*psychology | 2 | 13.0 |
District of Columbia | 4 | 40.0 |
European Continental Ancestry Group/*psychology | 2 | 33.0 |
Ovarian Neoplasms/*genetics/*prevention & control | 6 | 100.0 |
Adenocarcinoma/*genetics/pathology | 2 | 2.0 |
Nocodazole/pharmacology | 5 | 3.0 |
Mammary Neoplasms, Animal/genetics | 2 | 40.0 |
Diagnosis, Differential | 4 | 0.0 |
Ultrasonography, Doppler, Color | 2 | 9.0 |
Endometriosis/*genetics | 2 | 11.0 |
Repressor Proteins/*metabolism | 2 | 1.0 |
Breast Neoplasms/*genetics/pathology/*therapy | 2 | 50.0 |
France/epidemiology | 5 | 3.0 |
Menarche | 2 | 10.0 |
Spain/ethnology | 2 | 6.0 |
Health Services Research | 2 | 11.0 |
Chromosome Mapping/methods | 3 | 2.0 |
Esophageal Neoplasms/*genetics | 2 | 2.0 |
Ovarian Neoplasms/diagnosis/epidemiology/genetics | 2 | 100.0 |
Iceland | 3 | 7.0 |
Risk Assessment/statistics & numerical data | 2 | 40.0 |
Belgium | 2 | 3.0 |
Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 0.0 |
BRCA1 Protein/genetics/immunology/*metabolism | 3 | 100.0 |
Immunoassay | 2 | 0.0 |
DNA-Binding Proteins/analysis/genetics | 2 | 11.0 |
DNA Transposable Elements | 6 | 4.0 |
Adenocarcinoma/genetics | 2 | 2.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 3 | 0.0 |
Tumor Markers, Biological/metabolism | 5 | 1.0 |
*Dosage Compensation (Genetics) | 3 | 1.0 |
Linear Models | 5 | 1.0 |
Estrogen Antagonists/therapeutic use | 4 | 33.0 |
Cell Cycle Proteins/genetics/*metabolism | 6 | 4.0 |
Chromosomal Proteins, Non-Histone/genetics/*metabolism | 2 | 12.0 |
Protein Transport | 2 | 0.0 |
Genetic Screening/methods/statistics & numerical data | 2 | 50.0 |
Cystadenocarcinoma/*genetics | 2 | 100.0 |
BRCA1 Protein/*chemistry/metabolism | 7 | 100.0 |
Recombinant Proteins/chemistry/metabolism | 3 | 0.0 |
Breast Neoplasms/chemistry/genetics/*metabolism | 3 | 100.0 |
Ovarian Neoplasms/genetics/pathology | 2 | 14.0 |
*Microsatellite Repeats | 4 | 1.0 |
Teaching Materials | 3 | 27.0 |
Species Specificity | 7 | 0.0 |
*Chemoprevention | 2 | 28.0 |
Retinoids/therapeutic use | 2 | 66.0 |
Bayes Theorem | 3 | 5.0 |
Receptors, Progesterone/*analysis | 2 | 0.0 |
Cyprus/epidemiology | 2 | 20.0 |
Tay-Sachs Disease/genetics | 2 | 50.0 |
Databases | 2 | 2.0 |
Carcinoma, Ductal, Breast/*genetics | 6 | 24.0 |
*Chromosomes, Human, Pair 13 | 6 | 3.0 |
Phosphoric Monoester Hydrolases/*genetics | 3 | 1.0 |
Breast Neoplasms/ethnology/*genetics/*psychology | 2 | 100.0 |
Breast Neoplasms/*epidemiology/genetics | 3 | 60.0 |
Observer Variation | 2 | 1.0 |
Apoptosis/radiation effects | 2 | 5.0 |
DNA-Binding Proteins/*chemistry | 2 | 2.0 |
BRCA2 Protein/physiology | 3 | 100.0 |
Phosphopeptides/metabolism | 2 | 6.0 |
Chromosome Painting | 2 | 4.0 |
Metaphase | 3 | 2.0 |
Pancreatic Neoplasms/genetics/pathology | 2 | 25.0 |
Cell Cycle Proteins/genetics/metabolism | 2 | 2.0 |
Serine/chemistry | 3 | 2.0 |
Ovarian Neoplasms/genetics/psychology | 2 | 100.0 |
Neoplasms, Second Primary/*genetics | 3 | 14.0 |
Ovarian Neoplasms/complications/*genetics | 3 | 75.0 |
BRCA1 Protein/analysis/*metabolism | 4 | 100.0 |
Breast | 3 | 9.0 |
Neoplastic Syndromes, Hereditary/*pathology | 2 | 33.0 |
Tumor Markers, Biological | 7 | 1.0 |
Cell Nucleus/ultrastructure | 2 | 1.0 |
Randomized Controlled Trials | 2 | 0.0 |
Chromosome Mapping/*methods | 5 | 2.0 |
Phosphoproteins/*metabolism | 3 | 0.0 |
Data Interpretation, Statistical | 3 | 1.0 |
Stilbenes/*pharmacology | 2 | 3.0 |
Electrophoresis/*methods | 2 | 8.0 |
Lymphatic Metastasis/pathology | 2 | 2.0 |
*Phosphoric Monoester Hydrolases | 3 | 6.0 |
Protein-Tyrosine-Phosphatase/*genetics | 3 | 2.0 |
Genetic Predisposition to Disease/genetics/*psychology | 2 | 100.0 |
*Sick Role | 2 | 14.0 |
DNA Ligases/genetics/*metabolism | 2 | 28.0 |
Breast/chemistry | 2 | 9.0 |
Prenatal Diagnosis/*methods | 2 | 1.0 |
Oncogenes/genetics | 5 | 7.0 |
Breast Neoplasms/metabolism/pathology | 2 | 5.0 |
RNA, Messenger/analysis/biosynthesis | 2 | 0.0 |
*Disease Susceptibility | 2 | 15.0 |
Austria | 2 | 3.0 |
Recurrence | 5 | 0.0 |
Cyclins/biosynthesis | 2 | 2.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis | 2 | 1.0 |
*Trans-Activators | 2 | 0.0 |
Transcription Factors/biosynthesis | 2 | 2.0 |
European Continental Ancestry Group | 5 | 0.0 |
Estrogens/*physiology | 2 | 5.0 |
Ovarian Neoplasms/genetics/metabolism | 2 | 25.0 |
Genetic Research | 2 | 66.0 |
Physician-Patient Relations | 2 | 7.0 |
*Prenatal Diagnosis | 2 | 0.0 |
Chromosome Aberrations/genetics | 4 | 3.0 |
Scotland | 2 | 5.0 |
Cross Reactions | 2 | 0.0 |
Cytokines/*genetics | 2 | 1.0 |
*Virus Integration | 2 | 2.0 |
RNA, Messenger/drug effects/metabolism | 2 | 1.0 |
Confidentiality | 2 | 33.0 |
Human Genome Project | 2 | 12.0 |
Breast Neoplasms/*genetics/therapy | 4 | 44.0 |
Nucleic Acid Heteroduplexes/analysis | 2 | 22.0 |
*Smoking | 2 | 2.0 |
Cosmids | 7 | 1.0 |
Iran/ethnology | 2 | 25.0 |
Neoplasms, Multiple Primary/genetics | 5 | 33.0 |
*Mitosis | 6 | 4.0 |
Models, Chemical | 3 | 0.0 |
Oxidation-Reduction | 3 | 0.0 |
Breast Neoplasms/etiology/genetics | 2 | 28.0 |
Molecular Structure | 2 | 0.0 |
Phosphopeptides/*metabolism | 2 | 20.0 |
*Genetic Heterogeneity | 4 | 2.0 |
African Continental Ancestry Group/genetics | 4 | 1.0 |
North Carolina/epidemiology | 2 | 11.0 |
*Pedigree | 3 | 10.0 |
Research | 2 | 3.0 |
Cytoplasm/chemistry | 3 | 1.0 |
Epithelial Cells | 8 | 1.0 |
Luciferases/biosynthesis | 2 | 2.0 |
Oligodeoxyribonucleotides | 3 | 0.0 |
Alternative Splicing/genetics | 4 | 2.0 |
Mammary Neoplasms, Experimental/genetics/pathology | 2 | 28.0 |
Neoplasms, Experimental/*genetics/pathology | 2 | 25.0 |
Neoplasm Proteins/*analysis | 3 | 0.0 |
Transcription Factors/*analysis | 3 | 5.0 |
Receptors, Progesterone/metabolism | 6 | 3.0 |
England | 2 | 1.0 |
Breast Neoplasms/genetics/*mortality/pathology | 2 | 100.0 |
Ovarian Neoplasms/genetics/*mortality/pathology | 2 | 100.0 |
Chromosomes, Human, Pair 13 | 6 | 4.0 |
Saccharomyces cerevisiae | 3 | 1.0 |
DNA Primers/analysis/chemistry/genetics | 2 | 18.0 |
DNA, Neoplasm/analysis/chemistry/genetics | 2 | 20.0 |
Hela Cells/pathology | 2 | 40.0 |
Mammary Glands, Human/cytology | 2 | 66.0 |
Korea | 2 | 0.0 |
Protein Kinases/genetics/*metabolism | 2 | 2.0 |
*Informed Consent | 2 | 66.0 |
Antibodies | 3 | 0.0 |
Subcellular Fractions/chemistry | 2 | 3.0 |
*Genes, APC | 2 | 2.0 |
DNA, Neoplasm/isolation & purification | 2 | 6.0 |
*Mass Screening | 2 | 3.0 |
*Chromosome Mapping | 8 | 0.0 |
BRCA2 Protein/genetics/*metabolism | 2 | 40.0 |
*Sex Ratio | 2 | 20.0 |
Polymorphism, Single Nucleotide/*genetics | 3 | 1.0 |
Melanoma/genetics | 2 | 5.0 |
Uncertainty | 2 | 66.0 |
RNA, Messenger/*analysis | 2 | 0.0 |
Oncogenes | 7 | 2.0 |
Patents/*legislation & jurisprudence | 2 | 66.0 |
Genes, APC | 2 | 2.0 |
Cell Cycle/genetics/*physiology | 2 | 10.0 |
Mammary Glands, Animal/metabolism | 3 | 15.0 |
Epidermal Growth Factor/pharmacology | 2 | 0.0 |
G1 Phase/*genetics | 2 | 9.0 |
Leucine Zippers | 3 | 1.0 |
Tyrosine/metabolism | 2 | 0.0 |
Binding, Competitive | 3 | 0.0 |
Protein p53/*genetics/physiology | 2 | 15.0 |
Exodeoxyribonucleases/metabolism | 2 | 15.0 |
Causality | 6 | 15.0 |
Disclosure | 2 | 50.0 |
*Proto-Oncogenes | 6 | 0.0 |
Fungal Proteins/biosynthesis | 2 | 14.0 |
Tumor Markers, Biological/*analysis | 3 | 0.0 |
Chromatography, Gel | 3 | 0.0 |
Crosses, Genetic | 3 | 0.0 |
Electrophoresis, Agar Gel | 4 | 0.0 |
Interphase | 2 | 1.0 |
Software | 3 | 1.0 |
World Health | 2 | 3.0 |
Escherichia coli/metabolism | 2 | 0.0 |
Neoplasms, Radiation-Induced/epidemiology/*etiology/genetics | 2 | 100.0 |
Chromosomes, Human, Pair 5 | 2 | 1.0 |
Contraceptives, Oral | 2 | 14.0 |
*Repetitive Sequences, Nucleic Acid | 4 | 1.0 |
Viral Proteins/genetics/*metabolism | 2 | 3.0 |
Neoplasms/*prevention & control | 2 | 22.0 |
Neoplasm Proteins/chemistry/*genetics | 2 | 6.0 |
Transcription Factors/chemistry/*genetics | 2 | 2.0 |
*Counseling | 2 | 33.0 |
Disease Susceptibility/*diagnosis | 2 | 66.0 |
*Patient Education | 2 | 5.0 |
Estradiol/*pharmacology | 3 | 1.0 |
Korea/epidemiology | 2 | 3.0 |
Cell Cycle Proteins/antagonists & inhibitors/metabolism | 2 | 50.0 |
G1 Phase/physiology | 3 | 4.0 |
Biophysics | 2 | 4.0 |
Breast Neoplasms/*epidemiology | 2 | 18.0 |
Cell Nucleus/*chemistry | 2 | 5.0 |
*Disclosure | 3 | 60.0 |
Receptor, erbB-2 | 3 | 1.0 |
*Multigene Family | 2 | 0.0 |
DNA Fingerprinting | 2 | 1.0 |
*Attitude of Health Personnel | 2 | 15.0 |
Physician's Practice Patterns | 3 | 7.0 |
BRCA1 Protein | 96 | 94.0 |
Isoenzymes/*genetics | 2 | 0.0 |
Carcinoma in Situ/*genetics | 2 | 22.0 |
DNA, Satellite/genetics | 6 | 5.0 |
Fetal Death/genetics | 2 | 9.0 |
Oligodeoxyribonucleotides/genetics | 2 | 2.0 |
Breast Neoplasms/*genetics/*therapy | 2 | 66.0 |
Cytochrome P-450 Enzyme System/genetics | 2 | 1.0 |
Ovarian Neoplasms/*prevention & control | 2 | 100.0 |
Trinucleotide Repeats | 2 | 1.0 |
Breast/cytology/*metabolism | 2 | 8.0 |
Epithelium/metabolism | 2 | 0.0 |
Transcription Factors/*chemistry | 2 | 4.0 |
Proto-Oncogenes | 2 | 1.0 |
*Acid Anhydride Hydrolases | 3 | 1.0 |
Breast Neoplasms/*chemistry/ultrastructure | 2 | 50.0 |
Breast Neoplasms/*diagnosis/epidemiology/*genetics | 2 | 66.0 |
Neoplastic Syndromes, Hereditary/genetics/pathology | 2 | 100.0 |
Chromosomes, Human, Pair 11 | 3 | 0.0 |
Obesity | 2 | 3.0 |
*Nucleic Acid Hybridization | 2 | 3.0 |
Czech Republic/epidemiology | 2 | 13.0 |
Ethnic Groups/*genetics | 2 | 1.0 |
BRCA2 Protein/*biosynthesis | 2 | 100.0 |
*In Situ Hybridization, Fluorescence | 2 | 1.0 |
Lymph Nodes/pathology | 2 | 0.0 |
Japan/epidemiology | 3 | 0.0 |
Gene Expression Profiling/*methods | 2 | 2.0 |
Oligonucleotide Probes | 3 | 0.0 |
Tumor Markers, Biological/genetics/*metabolism | 2 | 5.0 |
Tumor Suppressor Proteins/genetics/metabolism | 2 | 6.0 |
DNA/analysis | 3 | 0.0 |
Colorectal Neoplasms/*genetics/pathology | 2 | 2.0 |
Universities | 2 | 40.0 |
National Institutes of Health (U.S.)/*legislation & jurisprudence | 2 | 100.0 |
Anxiety/etiology | 2 | 33.0 |
Chromosome Banding | 3 | 0.0 |
DNA, Satellite/analysis | 2 | 6.0 |
*G2 Phase | 3 | 8.0 |
Breast Neoplasms/*genetics/*prevention & control/surgery | 2 | 100.0 |
DNA/genetics/isolation & purification | 2 | 0.0 |
Calorimetry | 2 | 3.0 |
Neoplastic Syndromes, Hereditary/epidemiology | 2 | 100.0 |
Virus Replication | 2 | 0.0 |
Breast Neoplasms/drug therapy/*genetics | 2 | 25.0 |
Tamoxifen/adverse effects/therapeutic use | 2 | 100.0 |
DNA Replication/*physiology | 2 | 5.0 |
Tumor Suppressor Proteins/genetics/*metabolism | 2 | 3.0 |
*Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Estradiol Dehydrogenases/genetics | 3 | 100.0 |
Breast Neoplasms/enzymology/*genetics | 2 | 7.0 |
Genes, Structural | 2 | 0.0 |
*Muscle Proteins | 2 | 0.0 |
Ovarian Neoplasms/*genetics/therapy | 2 | 100.0 |
17-Hydroxysteroid Dehydrogenases/*genetics | 2 | 33.0 |
Hybrid Cells/radiation effects | 3 | 7.0 |
*Risk Assessment | 2 | 11.0 |
Thyroid Neoplasms/*genetics | 2 | 2.0 |
Breast Neoplasms/*diagnosis | 2 | 11.0 |
Mass Screening/methods | 3 | 6.0 |
Biopsy, Needle | 3 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/genetics | 2 | 8.0 |
Receptors, Retinoic Acid/genetics | 3 | 3.0 |
p14ARF Protein/genetics | 2 | 9.0 |
India | 4 | 1.0 |
Cell Fusion | 2 | 0.0 |
Drosophila/genetics | 2 | 1.0 |
Genes, p53/physiology | 3 | 11.0 |
Ovarian Neoplasms/*genetics/*pathology | 2 | 22.0 |
Genetic Predisposition to Disease/epidemiology/*genetics | 3 | 16.0 |
BRCA1 Protein/chemistry | 2 | 100.0 |
Carrier Proteins/chemistry | 3 | 7.0 |
Hysterectomy | 2 | 2.0 |
Phosphoserine/metabolism | 2 | 2.0 |
RNA, Small Interfering | 2 | 3.0 |
Nuclear Proteins/*chemistry/*metabolism | 2 | 9.0 |
Neoplasms/*genetics/pathology | 2 | 5.0 |
Mitomycin/metabolism | 2 | 40.0 |
BRCA1 Protein/biosynthesis/*physiology | 2 | 100.0 |
*Child Development | 3 | 10.0 |
Electroencephalography | 3 | 1.0 |
Motor Cortex/*anatomy & histology/*growth & development | 3 | 23.0 |
Seizures/surgery | 3 | 23.0 |
Skull/*anatomy & histology/*growth & development | 3 | 23.0 |
Breast Neoplasms/*genetics/pathology/*surgery | 2 | 100.0 |
Neoplasms/*genetics/*metabolism | 3 | 60.0 |
RNA Splice Sites | 3 | 10.0 |
Sequence Analysis, RNA | 2 | 5.0 |
Cattle | 3 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Mutagenicity Tests | 3 | 1.0 |
RNA, Small Interfering/pharmacology | 3 | 3.0 |
DNA Repair/drug effects | 2 | 6.0 |
Population Surveillance/methods | 2 | 18.0 |
DNA/genetics/metabolism | 2 | 0.0 |
Genes, Recessive | 2 | 0.0 |
Lysine/metabolism | 2 | 2.0 |
Asian Continental Ancestry Group | 2 | 0.0 |
*DNA Damage/radiation effects | 4 | 40.0 |
Nuclear Proteins/chemistry/genetics/*metabolism | 2 | 2.0 |
Consanguinity | 3 | 0.0 |
Chile | 3 | 5.0 |
Meta-Analysis | 2 | 1.0 |
Tretinoin/pharmacology | 2 | 0.0 |
Breast Neoplasms/*chemically induced/genetics | 3 | 100.0 |
Confounding Factors (Epidemiology) | 2 | 3.0 |
Contraceptives, Oral, Hormonal/*adverse effects | 3 | 33.0 |
Spouses/*psychology | 2 | 100.0 |
*Genetic Vectors | 2 | 0.0 |
Gene Rearrangement/*genetics | 2 | 5.0 |
RNA Splice Sites/*genetics | 2 | 5.0 |
Protein Interaction Mapping | 2 | 1.0 |
G2 Phase/genetics/*physiology | 2 | 25.0 |
*Genes, cdc | 2 | 9.0 |
Recombinant Fusion Proteins/physiology | 2 | 0.0 |
*Oxidative Stress | 2 | 0.0 |
Tumor Markers, Biological/*metabolism | 3 | 0.0 |
Breast Neoplasms/*metabolism/mortality/pathology | 2 | 20.0 |
Electrophoretic Mobility Shift Assay | 2 | 0.0 |
Antineoplastic Agents/*toxicity | 2 | 3.0 |
Neoplasms/metabolism | 3 | 3.0 |
Gene Expression/genetics | 2 | 0.0 |
*S Phase/radiation effects | 2 | 66.0 |
*Macromolecular Substances | 2 | 40.0 |
Neoplasm Proteins/chemistry/physiology | 2 | 33.0 |
Perception | 2 | 14.0 |
Ovarian Neoplasms/genetics/surgery | 2 | 100.0 |
